

**Universal Vision Biotechnology Co., Ltd.
and Subsidiaries**

**Consolidated Financial Statements for the
Nine Months Ended September 30, 2025 and 2024 and
Independent Auditors' Review Report**

INDEPENDENT AUDITORS' REVIEW REPORT

The Board of Directors and Shareholders
Universal Vision Biotechnology Co., Ltd.

Introduction

We have reviewed the accompanying consolidated balance sheets of Universal Vision Biotechnology Co., Ltd. and its subsidiaries (collectively, the “Group”) as of September 30, 2025 and 2024, the related consolidated statements of comprehensive income for the three months ended September 30, 2025 and 2024 and for the nine months ended September 30, 2025 and 2024, the consolidated statements of changes in equity and cash flows for the nine months then ended, and the related notes to the consolidated financial statements, including material accounting policy information (collectively referred to as the “consolidated financial statements”). Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers, and International Accounting Standard 34 “Interim Financial Reporting” endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China. Our responsibility is to express a conclusion on the consolidated financial statements based on our reviews.

Scope of Review

We conducted our reviews in accordance with the Standards on Review Engagements of the Republic of China 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”. A review of consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our reviews, nothing has come to our attention that caused us to believe that the accompanying consolidated financial statements do not present fairly, in all material respects, the consolidated financial position of the Group as of September 30, 2025 and 2024, its consolidated financial performance for the three months ended September 30, 2025 and 2024, and its consolidated financial performance and its consolidated cash flows for the nine months ended September 30, 2025 and 2024 in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers, and International Accounting Standard 34 “Interim Financial Reporting” endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China.

The engagement partners on the reviews resulting in this independent auditors' review report are Wan-I Liao and Tsung-Yuan Tsai.

Deloitte & Touche
Taipei, Taiwan
Republic of China

November 12, 2025

Notice to Readers

The accompanying consolidated financial statements are intended only to present the consolidated financial position, financial performance and cash flows in accordance with accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions. The standards, procedures and practices to review such consolidated financial statements are those generally applied in the Republic of China.

For the convenience of readers, the independent auditors' review report and the accompanying consolidated financial statements have been translated into English from the original Chinese version prepared and used in the Republic of China. If there is any conflict between the English version and the original Chinese version or any difference in the interpretation of the two versions, the Chinese-language independent auditors' review report and consolidated financial statements shall prevail.

UNIVERSAL VISION BIOTECHNOLOGY CO., LTD. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS (In Thousands of New Taiwan Dollars)

ASSETS	September 30, 2025		December 31, 2024		September 30, 2024	
	Amount	%	Amount	%	Amount	%
CURRENT ASSETS						
Cash and cash equivalents (Note 6)	\$ 638,388	11	\$ 506,854	9	\$ 503,908	9
Financial assets at fair value through profit or loss - current (Note 7)	1,216,352	20	1,295,373	22	1,284,206	22
Financial assets at amortized cost - current (Notes 9 and 10)	86,770	1	115,216	2	282,641	5
Trade receivables (Note 11)	518,650	9	565,569	10	539,523	9
Other receivables	9,618	-	11,897	-	12,127	-
Inventories (Note 12)	338,591	6	289,725	5	280,963	5
Other current assets	63,946	1	57,187	1	60,441	1
Total current assets	<u>2,872,315</u>	<u>48</u>	<u>2,841,821</u>	<u>49</u>	<u>2,963,809</u>	<u>51</u>
NON-CURRENT ASSETS						
Financial assets at fair value through other comprehensive income - non-current (Notes 4, 8 and 10)	105,919	2	111,073	2	117,007	2
Property, plant and equipment (Notes 14 and 32)	1,875,270	32	1,756,259	31	1,749,455	30
Right-of-use assets (Note 15)	932,598	16	917,162	16	858,309	15
Intangible assets (Note 16)	22,293	-	22,790	-	23,191	-
Deferred tax assets (Note 4)	71,532	1	72,259	1	72,526	1
Prepayments for equipment	17,342	-	-	-	1,268	-
Refundable deposits	41,948	1	41,202	1	39,224	1
Other non-current assets (Note 32)	128	-	136	-	770	-
Total non-current assets	<u>3,067,030</u>	<u>52</u>	<u>2,920,881</u>	<u>51</u>	<u>2,861,750</u>	<u>49</u>
TOTAL	<u>\$ 5,939,345</u>	<u>100</u>	<u>\$ 5,762,702</u>	<u>100</u>	<u>\$ 5,825,559</u>	<u>100</u>
LIABILITIES AND EQUITY						
CURRENT LIABILITIES						
Short-term borrowings (Notes 17 and 32)	\$ 229,149	4	\$ 92,012	2	\$ 476,968	8
Trade payables (Note 18)	245,260	4	268,070	5	269,141	5
Payables for equipment (Note 20)	144,613	3	91,080	1	116,501	2
Other payables (Note 19)	235,349	4	277,453	5	263,471	4
Current tax liabilities (Note 4)	81,899	1	154,445	3	105,202	2
Lease liabilities - current (Note 15)	184,636	3	178,399	3	177,682	3
Other current liabilities (Note 23)	48,881	1	29,265	-	39,927	1
Total current liabilities	<u>1,169,787</u>	<u>20</u>	<u>1,090,724</u>	<u>19</u>	<u>1,448,892</u>	<u>25</u>
NON-CURRENT LIABILITIES						
Deferred tax liabilities (Note 4)	57,346	1	60,930	1	61,467	1
Lease liabilities - non-current (Note 15)	798,526	13	783,828	14	723,275	12
Long-term accounts payable (Note 20)	45,539	1	70,908	1	64,971	1
Guarantee deposits	584	-	584	-	544	-
Total non-current liabilities	<u>901,995</u>	<u>15</u>	<u>916,250</u>	<u>16</u>	<u>850,257</u>	<u>14</u>
Total liabilities	<u>2,071,782</u>	<u>35</u>	<u>2,006,974</u>	<u>35</u>	<u>2,299,149</u>	<u>39</u>
EQUITY ATTRIBUTABLE TO OWNERS OF THE COMPANY (Note 22)						
Share capital						
Ordinary shares	847,249	14	847,249	15	847,249	14
Capital surplus	381,924	6	381,924	7	381,924	7
Retained earnings						
Legal reserve	480,779	8	378,623	6	378,623	7
Special reserve	-	-	11,384	-	11,384	-
Unappropriated earnings	2,020,480	34	1,998,328	35	1,759,285	30
Total retained earnings	<u>2,501,259</u>	<u>42</u>	<u>2,388,335</u>	<u>41</u>	<u>2,149,292</u>	<u>37</u>
Other equity	(13,929)	-	4,505	-	9,150	-
Total equity attributable to owners of the Company	<u>3,716,503</u>	<u>62</u>	<u>3,622,013</u>	<u>63</u>	<u>3,387,615</u>	<u>58</u>
NON-CONTROLLING INTERESTS	<u>151,060</u>	<u>3</u>	<u>133,715</u>	<u>2</u>	<u>138,795</u>	<u>3</u>
Total equity	<u>3,867,563</u>	<u>65</u>	<u>3,755,728</u>	<u>65</u>	<u>3,526,410</u>	<u>61</u>
TOTAL	<u>\$ 5,939,345</u>	<u>100</u>	<u>\$ 5,762,702</u>	<u>100</u>	<u>\$ 5,825,559</u>	<u>100</u>

The accompanying notes are an integral part of the consolidated financial statements.

UNIVERSAL VISION BIOTECHNOLOGY CO., LTD. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (In Thousands of New Taiwan Dollars, Except Earnings Per Share)

	For the Three Months Ended September 30				For the Nine Months Ended September 30			
	2025		2024		2025		2024	
	Amount	%	Amount	%	Amount	%	Amount	%
OPERATING REVENUE (Note 23)	\$ 1,024,739	100	\$ 1,079,584	100	\$ 3,170,903	100	\$ 3,190,187	100
OPERATING COSTS (Notes 12 and 24)	<u>(420,361)</u>	<u>(41)</u>	<u>(448,840)</u>	<u>(42)</u>	<u>(1,295,492)</u>	<u>(41)</u>	<u>(1,267,408)</u>	<u>(40)</u>
GROSS PROFIT	<u>604,378</u>	<u>59</u>	<u>630,744</u>	<u>58</u>	<u>1,875,411</u>	<u>59</u>	<u>1,922,779</u>	<u>60</u>
OPERATING EXPENSES (Notes 11, 21 and 24)								
Selling and marketing expenses	(183,058)	(18)	(195,225)	(18)	(521,450)	(16)	(553,181)	(17)
General and administrative expenses	(106,555)	(10)	(111,219)	(10)	(315,017)	(10)	(339,318)	(11)
Expected credit gain (loss)	<u>544</u>	<u>-</u>	<u>(271)</u>	<u>-</u>	<u>3,125</u>	<u>-</u>	<u>(33)</u>	<u>-</u>
Total operating expenses	<u>(289,069)</u>	<u>(28)</u>	<u>(306,715)</u>	<u>(28)</u>	<u>(833,342)</u>	<u>(26)</u>	<u>(892,532)</u>	<u>(28)</u>
PROFIT FROM OPERATIONS	<u>315,309</u>	<u>31</u>	<u>324,029</u>	<u>30</u>	<u>1,042,069</u>	<u>33</u>	<u>1,030,247</u>	<u>32</u>
NON-OPERATING INCOME AND EXPENSES (Note 24)								
Interest income	15,612	2	9,453	1	51,410	2	20,384	1
Other income	1,421	-	1,113	-	6,615	-	5,630	-
Other gains and losses	87,097	8	(20,516)	(2)	(89,873)	(3)	(14,898)	(1)
Finance costs	<u>(6,310)</u>	<u>(1)</u>	<u>(5,022)</u>	<u>-</u>	<u>(18,596)</u>	<u>(1)</u>	<u>(13,855)</u>	<u>-</u>
Total non-operating income and expenses	<u>97,820</u>	<u>9</u>	<u>(14,972)</u>	<u>(1)</u>	<u>(50,444)</u>	<u>(2)</u>	<u>(2,739)</u>	<u>-</u>
PROFIT BEFORE INCOME TAX	413,129	40	309,057	29	991,625	31	1,027,508	32
INCOME TAX EXPENSE (Notes 4 and 25)	<u>(63,297)</u>	<u>(6)</u>	<u>(64,884)</u>	<u>(6)</u>	<u>(229,042)</u>	<u>(7)</u>	<u>(210,147)</u>	<u>(7)</u>
NET PROFIT FOR THE PERIOD	<u>349,832</u>	<u>34</u>	<u>244,173</u>	<u>23</u>	<u>762,583</u>	<u>24</u>	<u>817,361</u>	<u>25</u>
OTHER COMPREHENSIVE INCOME (Notes 4, 22 and 25)								
Items that will not be reclassified subsequently to profit or loss:								
Unrealized gain on investments in equity instruments designated as at fair value through other comprehensive income	245	-	-	-	457	-	-	-
Items that may be reclassified subsequently to profit or loss:								
Exchange differences on translation of the financial statements of foreign operations	22,089	2	(4,689)	(1)	(32,274)	(1)	25,058	1
Unrealized gain on investments in debt instruments at fair value through other comprehensive income	1,629	-	6,457	1	1,783	-	6,323	-
Income tax relating to items that may be reclassified subsequently to profit or loss	<u>(3,804)</u>	<u>-</u>	<u>(560)</u>	<u>-</u>	<u>4,723</u>	<u>-</u>	<u>(5,133)</u>	<u>-</u>
Other comprehensive income (loss) for the period, net of income tax	<u>20,159</u>	<u>2</u>	<u>1,208</u>	<u>-</u>	<u>(25,311)</u>	<u>(1)</u>	<u>26,248</u>	<u>1</u>
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	<u>\$ 369,991</u>	<u>36</u>	<u>\$ 245,381</u>	<u>23</u>	<u>\$ 737,272</u>	<u>23</u>	<u>\$ 843,609</u>	<u>26</u>
NET PROFIT ATTRIBUTABLE TO:								
Owners of the Company	\$ 343,205	33	\$ 243,654	23	\$ 748,361	24	\$ 825,678	25
Non-controlling interests	<u>6,627</u>	<u>1</u>	<u>519</u>	<u>-</u>	<u>14,222</u>	<u>-</u>	<u>(8,317)</u>	<u>-</u>
	<u>\$ 349,832</u>	<u>34</u>	<u>\$ 244,173</u>	<u>23</u>	<u>\$ 762,583</u>	<u>24</u>	<u>\$ 817,361</u>	<u>25</u>
TOTAL COMPREHENSIVE INCOME ATTRIBUTABLE TO:								
Owners of the Company	\$ 358,666	35	\$ 245,892	23	\$ 729,927	23	\$ 846,212	26
Non-controlling interests	<u>11,325</u>	<u>1</u>	<u>(511)</u>	<u>-</u>	<u>7,345</u>	<u>-</u>	<u>(2,603)</u>	<u>-</u>
	<u>\$ 369,991</u>	<u>36</u>	<u>\$ 245,381</u>	<u>23</u>	<u>\$ 737,272</u>	<u>23</u>	<u>\$ 843,609</u>	<u>26</u>
EARNINGS PER SHARE (Note 26)								
Basic	<u>\$ 4.05</u>		<u>\$ 2.88</u>		<u>\$ 8.83</u>		<u>\$ 9.75</u>	
Diluted	<u>\$ 4.04</u>		<u>\$ 2.87</u>		<u>\$ 8.81</u>		<u>\$ 9.73</u>	

The accompanying notes are an integral part of the consolidated financial statements.

UNIVERSAL VISION BIOTECHNOLOGY CO., LTD. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
(In Thousands of New Taiwan Dollars)

	Equity Attributable to Owners of the Company						Other Equity			Total Equity
	Share Capital		Capital Surplus	Retained Earnings			Exchange Differences on Translating of the Financial Statements of Foreign Operations	Unrealized Valuation Gain (Loss) on Financial Assets at Fair Value Through Other Comprehensive Income	Non-controlling Interests (Note 22)	
	Shares (In Thousands)	Amount		Legal Reserve	Special Reserve	Unappropriated Earnings				
BALANCE ON JANUARY 1, 2024	84,725	\$ 847,249	\$ 381,924	\$ 278,614	\$ 5,042	\$ 1,676,197	\$ (11,384)	\$ -	\$ 165,333	\$ 3,342,975
Appropriation of 2023 earnings										
Legal reserve	-	-	-	100,009	-	(100,009)	-	-	-	-
Special reserve	-	-	-	-	6,342	(6,342)	-	-	-	-
Cash dividends distributed by the Company	-	-	-	-	-	(593,074)	-	-	-	(593,074)
Actual acquisition of interests in subsidiaries (Note 27)	-	-	-	-	-	(43,165)	-	-	(23,935)	(67,100)
Net profit for the nine months ended September 30, 2024	-	-	-	-	-	825,678	-	-	(8,317)	817,361
Other comprehensive income for the nine months ended September 30, 2024, net of income tax	-	-	-	-	-	-	15,476	5,058	5,714	26,248
Total comprehensive income (loss) for the nine months ended September 30, 2024	-	-	-	-	-	825,678	15,476	5,058	(2,603)	843,609
BALANCE ON SEPTEMBER 30, 2024	<u>84,725</u>	<u>\$ 847,249</u>	<u>\$ 381,924</u>	<u>\$ 378,623</u>	<u>\$ 11,384</u>	<u>\$ 1,759,285</u>	<u>\$ 4,092</u>	<u>\$ 5,058</u>	<u>\$ 138,795</u>	<u>\$ 3,526,410</u>
BALANCE ON JANUARY 1, 2025	84,725	\$ 847,249	\$ 381,924	\$ 378,623	\$ 11,384	\$ 1,998,328	\$ 7,352	\$ (2,847)	\$ 133,715	\$ 3,755,728
Appropriation of 2024 earnings										
Legal reserve	-	-	-	102,156	-	(102,156)	-	-	-	-
Cash dividends distributed by the Company	-	-	-	-	-	(635,437)	-	-	-	(635,437)
Reversal of special reserve	-	-	-	-	(11,384)	11,384	-	-	-	-
Non-controlling interests	-	-	-	-	-	-	-	-	10,000	10,000
Net profit for the nine months ended September 30, 2025	-	-	-	-	-	748,361	-	-	14,222	762,583
Other comprehensive income (loss) for the nine months ended September 30, 2025, net of income tax	-	-	-	-	-	-	(20,317)	1,883	(6,877)	(25,311)
Total comprehensive income (loss) for the nine months ended September 30, 2025	-	-	-	-	-	748,361	(20,317)	1,883	7,345	737,272
BALANCE ON SEPTEMBER 30, 2025	<u>84,725</u>	<u>\$ 847,249</u>	<u>\$ 381,924</u>	<u>\$ 480,779</u>	<u>\$ -</u>	<u>\$ 2,020,480</u>	<u>\$ (12,965)</u>	<u>\$ (964)</u>	<u>\$ 151,060</u>	<u>\$ 3,867,563</u>

The accompanying notes are an integral part of the consolidated financial statements.

UNIVERSAL VISION BIOTECHNOLOGY CO., LTD. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS (In Thousands of New Taiwan Dollars)

	For the Nine Months Ended September 30	
	2025	2024
CASH FLOWS FROM OPERATING ACTIVITIES		
Income before income tax	\$ 991,625	\$ 1,027,508
Adjustments for:		
Depreciation expense	401,473	381,524
Amortization expense	1,865	2,602
Expected credit loss (reversed) recognized on trade receivables	(3,125)	33
Net loss on fair value changes of financial assets at fair value through profit or loss	79,021	12,300
Finance costs	18,596	13,855
Interest income	(51,410)	(20,384)
Dividend income	(10)	-
Loss on disposal of property, plant and equipment	562	4,989
Loss on disposal of intangible assets	16	-
Write-down of inventories	-	9,274
Reversal of write-down of inventories	(21)	-
Net unrealized loss on foreign currency exchange	8,178	2,814
Gain and relief from lease modifications	-	(572)
Changes in operating assets and liabilities		
Trade receivables	50,274	44,609
Other receivables	659	(497)
Inventories	(48,717)	4,271
Other current assets	(6,759)	706
Trade payables	(22,810)	(43,167)
Other payables	(42,158)	2,218
Other current liabilities	19,616	10,808
Cash generated from operations	1,396,875	1,452,891
Interest received	51,676	12,420
Dividends received	5	-
Interest paid	(4,190)	(2,133)
Income taxes paid	(299,007)	(276,584)
Net cash generated from operating activities	<u>1,145,359</u>	<u>1,186,594</u>
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of financial assets at fair value through other comprehensive income	(848)	(113,521)
Proceeds from sale of financial assets at amortized cost	22,906	295,722
Purchase of financial assets at fair value through profit or loss	-	(1,296,506)
Payments for property, plant and equipment	(360,700)	(315,167)
Proceeds from disposal of property, plant and equipment	114	587
Increase in refundable deposits	(1,310)	(527)
Payments for intangible assets	(1,124)	(2,005)
Increase in prepayments for equipment	(17,342)	(382)
Net cash used in investing activities	<u>(358,304)</u>	<u>(1,431,799)</u>
CASH FLOWS FROM FINANCING ACTIVITIES		
Proceeds from short-term borrowings	179,813	467,838
Repayments of short-term borrowings	(40,138)	-
Repayments of long-term borrowings	-	(1,352)
Repayments of the principal portion of lease liabilities	(151,726)	(135,411)
Dividends paid to owners of the Company	(635,437)	(593,074)
Acquisition of additional interests in subsidiaries	-	(67,100)
Changes in non-controlling interests	10,000	-
Net cash used in financing activities	<u>(637,488)</u>	<u>(329,099)</u>
EFFECT OF EXCHANGE RATE CHANGES ON THE BALANCE OF CASH HELD IN FOREIGN CURRENCIES	<u>(18,033)</u>	<u>15,667</u>
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	131,534	(558,637)
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD	<u>506,854</u>	<u>1,062,545</u>
CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD	<u>\$ 638,388</u>	<u>\$ 503,908</u>

The accompanying notes are an integral part of the consolidated financial statements.

UNIVERSAL VISION BIOTECHNOLOGY CO., LTD. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024 (In Thousands of New Taiwan Dollars, Unless Stated Otherwise)

1. GENERAL INFORMATION

Universal Vision Biotechnology Co., Ltd. (the “Company”) was incorporated in Taipei under the laws of the Republic of China (ROC) in August 1994 and is mainly engaged in operating the business of (1) sales of optical devices, glasses, lenses and other vision aid products (2) optometric services (3) sales and leasing of medical devices (4) providing of hospital management and technical consultancy services.

The Company’s shares have been listed on the mainboard of the Taipei Exchange (“TPEX”) since November 2004.

The consolidated financial statements are presented in the Company’s functional currency, the New Taiwan dollar.

2. APPROVAL OF FINANCIAL STATEMENTS

The consolidated financial statements were approved by the Company’s board of directors on November 12, 2025.

3. APPLICATION OF NEW, AMENDED AND REVISED STANDARDS AND INTERPRETATIONS

- a. Initial application of the amendments to the International Financial Reporting Standards (IFRS), International Accounting Standards (IAS), IFRIC Interpretations (IFRIC), and SIC Interpretations (SIC) (collectively, the “IFRS Accounting Standards”) endorsed and issued into effect by the Financial Supervisory Commission (FSC)

The Company and entities controlled by the Company (collectively the “Group”).

Amendments to IAS 21 “Lack of Exchangeability”

The initial application of the Amendments to IAS 21 “Lack of Exchangeability” did not have a material impact on the Group’s accounting policies.

- b. The IFRS Accounting Standards endorsed by the FSC for application starting from 2026

<u>New, Amended and Revised Standards and Interpretations</u>	<u>Effective Date Announced by IASB</u>
Amendments to IFRS 9 and IFRS 7 “Amendments to the Classification and Measurement of Financial Instruments”	January 1, 2026
Amendments to IFRS 9 and IFRS 7 “Contracts Referencing Nature-dependent Electricity”	January 1, 2026
Annual Improvements to IFRS Accounting Standards - Volume 11	January 1, 2026
IFRS 17 “Insurance Contracts” (including the 2020 and 2021 amendments to IFRS 17)	January 1, 2023

Amendments to IFRS 9 and IFRS 7 “Amendments to the Classification and Measurement of Financial Instruments”

1) The amendments to the application guidance of classification of financial assets

The amendments mainly amend the requirements for the classification of financial assets, including:

- a) If a financial asset contains a contingent feature that could change the timing or amount of contractual cash flows and the contingent event itself does not relate directly to changes in basic lending risks and costs (e.g., whether the debtor achieves a contractually specified reduction in carbon emissions), the financial asset has contractual cash flows that are solely payments of principal and interest on the principal amount outstanding if, and only if,
 - In all possible scenarios (before and after the occurrence of a contingent event), the contractual cash flows are solely payments of principal and interest on the principal amount outstanding; and
 - In all possible scenarios, the contractual cash flows would not be significantly different from the contractual cash flows on a financial instrument with identical contractual terms, but without such a contingent feature.
- b) To clarify that a financial asset has non-recourse features if an entity’s ultimate right to receive cash flows is contractually limited to the cash flows generated by specified assets.
- c) To clarify that the characteristics of contractually linked instruments include a prioritization of payments to the holders of financial assets using multiple contractually linked instruments (tranches) established through a waterfall payment structure, resulting in concentrations of credit risk and a disproportionate allocation of cash shortfalls from the underlying pool between the tranches.

2) The amendments to the application guidance of derecognition of financial liabilities

The amendments mainly stipulate that a financial liability is derecognized on the settlement date. However, when settling a financial liability in cash using an electronic payment system, the Group can choose to derecognize the financial liability before the settlement date if, and only if, the Group has initiated a payment instruction that resulted in:

- The Group having no practical ability to withdraw, stop or cancel the payment instruction;
- The Group having no practical ability to access the cash to be used for settlement as a result of the payment instruction; and
- The settlement risk associated with the electronic payment system being insignificant.

An entity shall apply the amendments retrospectively but is not required to restate prior periods. The effect of initially applying the amendments shall be recognized as an adjustment to the opening balance at the date of initial application. An entity may restate prior periods if, and only if, it is possible to do so without the use of hindsight.

As of the date the consolidated financial statements were authorized for issue, the Group is continuously assessing the possible impact of the application of the amendments on the Group’s financial position and financial performance and will disclose the relevant impact when the assessment is completed.

- c. The IFRS Accounting Standards in issue but not yet endorsed and issued into effect by the FSC

<u>New, Amended and Revised Standards and Interpretations</u>	<u>Effective Date Announced by IASB (Note 1)</u>
Amendments to IFRS 10 and IAS 28 “Sale or Contribution of Assets between an Investor and its Associate or Joint Venture”	To be determined by IASB
IFRS 18 “Presentation and Disclosure in Financial Statements”	January 1, 2027 (Note 2)
IFRS 19 “Subsidiaries without Public Accountability: Disclosures” (including the 2025 amendments to IFRS 19)	January 1, 2027

Note 1: Unless stated otherwise, the above IFRS Accounting Standards are effective for annual reporting periods beginning on or after their respective effective dates.

Note 2: On September 25, 2025, the FSC announced that IFRS 18 will take effect starting from January 1, 2028. Domestic entities could elect to apply IFRS 18 for an earlier period after the endorsement of IFRS 18 by the FSC.

- 1) Amendments to IFRS 10 and IAS 28 “Sale or Contribution of Assets between an Investor and its Associate or Joint Venture”

The amendments stipulate that, when the Group sells or contributes assets that constitute a business (as defined in IFRS 3) to an associate or joint venture, the gain or loss resulting from the transaction is recognized in full. Also, when the Group loses control of a subsidiary that contains a business but retains significant influence or joint control, the gain or loss resulting from the transaction is recognized in full.

Conversely, when the Group sells or contributes assets that do not constitute a business to an associate or joint venture, the gain or loss resulting from the transaction is recognized only to the extent of the Group’s interest as an unrelated investor in the associate or joint venture, i.e., the Group’s share of the gain or loss is eliminated. Also, when the Group loses control of a subsidiary that does not contain a business but retains significant influence or joint control over an associate or a joint venture, the gain or loss resulting from the transaction is recognized only to the extent of the Group’s interest as an unrelated investor in the associate or joint venture, i.e., the Group’s share of the gain or loss is eliminated.

- 2) IFRS 18 “Presentation and Disclosure in Financial Statements”

IFRS 18 will supersede IAS 1 “Presentation of Financial Statements”. The main changes comprise:

- Items of income and expenses included in the statement of profit or loss shall be classified into the operating, investing, financing, income taxes and discontinued operations categories.
- The statement of profit or loss shall present totals and subtotals for operating profit or loss, profit or loss before financing and income taxes and profit or loss.
- Provides guidance to enhance the requirements of aggregation and disaggregation: The Group shall identify the assets, liabilities, equity, income, expenses and cash flows that arise from individual transactions or other events and shall classify and aggregate them into groups based on shared characteristics, so as to result in the presentation in the primary financial statements of line items that have at least one similar characteristic. The Group shall disaggregate items with dissimilar characteristics in the primary financial statements and in the notes. The Group labels items as “other” only if it cannot find a more informative label.

- Disclosures on Management-defined Performance Measures (MPMs): When in public communications outside financial statements and communicating to users of financial statements management's view of an aspect of the financial performance of the Group as a whole, the Group shall disclose related information about its MPMs in a single note to the financial statements, including the description of such measures, calculations, reconciliations to the subtotal or total specified by IFRS Accounting Standards and the income tax and non-controlling interests effects of related reconciliation items.

Except for the above impact, as of the date the consolidated financial statements were authorized for issue, the Group is continuously assessing the other impacts of the above amended standards and interpretations on the Group's financial position and financial performance and will disclose the relevant impact when the assessment is completed.

4. SUMMARY OF MATERIAL ACCOUNTING POLICY INFORMATION

a. Statement of compliance

These interim consolidated financial statements have been prepared in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and IAS 34 "Interim Financial Reporting" as endorsed and issued into effect by the FSC. Disclosure information included in these interim consolidated financial statements is less than the disclosure information required in a complete set of annual consolidated financial statements.

b. Basis of preparation

The consolidated financial statements have been prepared on the historical cost basis except for financial instruments which are measured at fair value.

The fair value measurements, which are grouped into Levels 1 to 3 based on the degree to which the fair value measurement inputs are observable and based on the significance of the inputs to the fair value measurement in its entirety, are described as follows:

- 1) Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities;
- 2) Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for an asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices); and
- 3) Level 3 inputs are unobservable inputs for the asset or liability.

c. Basis of consolidation

The consolidated financial statements incorporate the financial statements of the Company and the entities controlled by the Company (i.e., its subsidiaries). Income and expenses of subsidiaries acquired or disposed of during the period are included in the consolidated statement of profit or loss and other comprehensive income from the effective dates of acquisitions up to the effective dates of disposals, as appropriate. When necessary, adjustments are made to the financial statements of subsidiaries to bring their accounting policies into line with those used by the Group. All intra-group transactions, balances, income and expenses are eliminated in full upon consolidation. Total comprehensive income of subsidiaries is attributed to the owners of the Company and to the non-controlling interests even if this results in the non-controlling interests having a deficit balance.

Changes in the Group's ownership interests in subsidiaries that do not result in the Group losing control over the subsidiaries are accounted for as equity transactions. The carrying amounts of the interests of the Group and the non-controlling interests are adjusted to reflect the changes in their relative interests in the subsidiaries. Any difference between the amount by which the non-controlling interests are adjusted and the fair value of the consideration paid or received is recognized directly in equity and attributed to the owners of the Company.

See Notes 13 and 35, Tables 4 and 5 for detailed information on subsidiaries (including percentages of ownership and main businesses).

d. Other material accounting policies

Except for the following, please refer to the consolidated financial statements for the year ended December 31, 2024.

1) Income tax expense

Income tax expense represents the sum of the tax currently payable and deferred tax. Interim period income taxes are assessed on an annual basis and calculated by applying to an interim period's pre-tax income the tax rate that would be applicable to expected total annual earnings.

2) Investments in equity instruments at FVTOCI

On initial recognition, the Group may make an irrevocable election to designate investments in equity instruments as at FVTOCI. Designation as at FVTOCI is not permitted if the equity investment is held for trading or if it is contingent consideration recognized by an acquirer in a business combination.

Investments in equity instruments at FVTOCI are subsequently measured at fair value with gains and losses arising from changes in fair value recognized in other comprehensive income and accumulated in other equity. The cumulative gain or loss will not be reclassified to profit or loss on disposal of the equity investments; instead, it will be transferred to retained earnings.

Dividends on these investments in equity instruments are recognized in profit or loss when the Group's right to receive the dividends is established, unless the dividends clearly represent a recovery of part of the cost of the investment.

5. MATERIAL ACCOUNTING JUDGMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY

In the application of the Group's accounting policies, management is required to make judgments, estimations, and assumptions on the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered relevant. Actual results may differ from these estimates.

When developing material accounting estimates, the Group considers the possible impact of climate change and related government policies and regulations on the cash flow projection, growth rates, discount rates, profitability and other relevant material estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Refer to the consolidated financial statements for the year ended December 31, 2024.

6. CASH AND CASH EQUIVALENTS

	<u>September 30, 2025</u>	<u>December 31, 2024</u>	<u>September 30, 2024</u>
Cash on hand	\$ 3,415	\$ 2,105	\$ 1,114
Checking accounts and demand deposits	514,980	435,486	476,873
Cash equivalents			
Time deposits	65,503	43,328	-
Repurchase agreements collateralized by bonds	<u>54,490</u>	<u>25,935</u>	<u>25,921</u>
	<u>\$ 638,388</u>	<u>\$ 506,854</u>	<u>\$ 503,908</u>

The market rate intervals for time deposits and repurchase agreements collateralized by bonds at the end of the reporting period were as follows:

	<u>September 30, 2025</u>	<u>December 31, 2024</u>	<u>September 30, 2024</u>
Time deposits	1.40%-1.60%	1.50%	-
Repurchase agreements collateralized by bonds	1.48%	1.47%	1.45%

7. FINANCIAL INSTRUMENTS AT FAIR VALUE THROUGH PROFIT OR LOSS

	<u>September 30, 2025</u>	<u>December 31, 2024</u>	<u>September 30, 2024</u>
<u>Financial assets at fair value through profit or loss (FVTPL) - current</u>			
Financial assets mandatorily classified as at FVTPL			
Non-derivative financial assets			
Mutual funds	<u>\$ 1,216,352</u>	<u>\$ 1,295,373</u>	<u>\$ 1,284,206</u>

Refer to Note 35, Table 2 for financial instruments measured at fair value through profit or loss. These financial assets are not pledged as collateral.

8. FINANCIAL ASSETS AT FAIR VALUE THROUGH OTHER COMPREHENSIVE INCOME

	<u>September 30, 2025</u>	<u>December 31, 2024</u>	<u>September 30, 2024</u>
<u>Non-current</u>			
Investments in equity instruments	\$ 1,305	\$ -	\$ -
Investments in debt instruments	<u>104,614</u>	<u>111,073</u>	<u>117,007</u>
	<u>\$ 105,919</u>	<u>\$ 111,073</u>	<u>\$ 117,007</u>

a. Investments in equity instruments

	<u>September 30, 2025</u>	<u>December 31, 2024</u>	<u>September 30, 2024</u>
<u>Non-current</u>			
Domestic investments			
Listed stocks	\$ <u>1,305</u>	\$ <u>-</u>	\$ <u>-</u>

These investments in equity instruments are held for medium- to long-term strategic purposes. Accordingly, the management elected to designate these investments in equity instruments as at FVTOCI as they believe that recognizing short-term fluctuations in these investments' fair value in profit or loss would not be consistent with the Group's strategy of holding these investments for long-term purposes.

Investments in equity instruments at FVTOCI were not pledged as collateral.

b. Investments in debt instruments

	<u>September 30, 2025</u>	<u>December 31, 2024</u>	<u>September 30, 2024</u>
<u>Non-current</u>			
Foreign investments			
U.S. Treasury bonds	\$ <u>104,614</u>	\$ <u>111,073</u>	\$ <u>117,007</u>

1) In 2024, the Group bought 20-year and 30-year U.S. Treasury bonds with a coupon rate of 4.75% and an effective interest rate of 4.47%-4.69%.

2) Refer to Note 10 for information relating to the credit risk management and impairment of investments in debt instruments at fair value through other comprehensive income.

3) Refer to Note 35, Table 2 for information relating to the breakdown below at fair value through other comprehensive income, the financial assets were not pledged as collateral.

9. FINANCIAL ASSETS AT AMORTIZED COST

	<u>September 30, 2025</u>	<u>December 31, 2024</u>	<u>September 30, 2024</u>
<u>Current</u>			
Domestic investments			
Time deposits with original maturities of more than 3 months (a)	\$ <u>86,770</u>	\$ <u>115,216</u>	\$ <u>282,641</u>

a. The ranges of interest rates for time deposits with original maturities of more than 3 months were approximately 1.70%-1.88%, 1.58%-2.00% and 1.58%-2.00% per annum as of September 30, 2025, December 31, 2024 and September 30, 2024, respectively.

b. Refer to Note 10 for information relating to the credit risk management and impairment of investments in financial assets at amortized cost.

10. CREDIT RISK MANAGEMENT FOR INVESTMENTS IN DEBT INSTRUMENTS

Investments in debt instruments classified as at FVTOCI and as at amortized cost were as follows:

September 30, 2025

	<u>At FVTOCI</u>	<u>At Amortized Cost</u>
Gross carrying amount	\$ 106,390	\$ 86,770
Less: Allowance for impairment loss	<u>-</u>	<u>-</u>
Amortized cost	106,390	<u>\$ 86,770</u>
Adjustment to fair value	<u>(1,776)</u>	
	<u>\$ 104,614</u>	

December 31, 2024

	<u>At FVTOCI</u>	<u>At Amortized Cost</u>
Gross carrying amount	\$ 114,632	\$ 115,216
Less: Allowance for impairment loss	<u>-</u>	<u>-</u>
Amortized cost	114,632	<u>\$ 115,216</u>
Adjustment to fair value	<u>(3,559)</u>	
	<u>\$ 111,073</u>	

September 30, 2024

	<u>At FVTOCI</u>	<u>At Amortized Cost</u>
Gross carrying amount	\$ 110,684	\$ 282,641
Less: Allowance for impairment loss	<u>-</u>	<u>-</u>
Amortized cost	110,684	<u>\$ 282,641</u>
Adjustment to fair value	<u>6,323</u>	
	<u>\$ 117,007</u>	

The policy adopted by the Group is to invest only in debt instruments with low credit risks. The Group takes into account the historical default loss rate and the expected prospect of the industry in which its business operates in the measurement of 12-month expected credit loss or expected lifetime credit loss of debt instruments. As of September 30, 2025, December 31, 2024 and September 30, 2024, due to the low credit risk of debtors and sufficient cash flow for contract settlements, provision for expected credit loss has not been made for financial assets at amortized cost and FVTOCI.

11. TRADE RECEIVABLES

	<u>September 30, 2025</u>	<u>December 31, 2024</u>	<u>September 30, 2024</u>
At amortized cost			
Gross carrying amount	\$ 530,866	\$ 581,144	\$ 552,640
Less: Allowance for impairment loss	<u>(12,216)</u>	<u>(15,575)</u>	<u>(13,117)</u>
	<u>\$ 518,650</u>	<u>\$ 565,569</u>	<u>\$ 539,523</u>

For the optometric segment, the sales of goods are paid by cash or with credit card. The average credit period for the ophthalmology business was 120 days from the end of the month and between 30-120 day from the date of the invoice; receivables are evaluated for any sign of impairment on the balance sheet date. If there is objective evidence that the estimated cash flow of accounts receivable will be adversely affected, such accounts receivable shall be assessed for impairment.

In order to minimize credit loss, the management of the Group has delegated a team responsible for determining credit limits, credit approvals and other monitoring procedures to ensure that follow-up action is taken to recover overdue debts.

The Group measures the loss allowance for trade receivables at an amount equal to lifetime ECLs. The expected credit losses on trade receivables are estimated using a provision matrix prepared by reference to the past default experience of the debtor and an analysis of the debtor's current financial position, adjusted for general economic conditions of the industry in which the debtors operate and an assessment of both the current as well as the forecasted direction of economic conditions at the reporting date. As the Group's historical credit loss experience does not show significantly different loss patterns for different customer segments, the provision for loss allowance based on past due status is not further distinguished according to the Group's different customer base.

The Group writes off a trade receivable when there is information indicating that the debtor is in severe financial difficulty and there is no realistic prospect of recovery. For trade receivables that have been written off, the Group continues to engage in enforcement activity to attempt to recover the receivables due. Where recoveries are made, these are recognized in profit or loss.

The following table details the loss allowance of trade receivables based on the Group's provision matrix.

September 30, 2025

	<u>Not Past Due</u>	<u>1 to 30 Days</u>	<u>31 to 60 Days</u>	<u>61 to 150 Days</u>	<u>Over 151 Days</u>	<u>Total</u>
Expected credit loss rate	0-19.21%	0-50%	0-100%	0-100%	0-100%	
Gross carrying amount	\$ 505,805	\$ 6,228	\$ 3,822	\$ 1,887	\$ 13,124	\$ 530,866
Loss allowance	<u>(89)</u>	<u>(61)</u>	<u>(213)</u>	<u>(394)</u>	<u>(11,459)</u>	<u>(12,216)</u>
Amortized cost	<u>\$ 505,716</u>	<u>\$ 6,167</u>	<u>\$ 3,609</u>	<u>\$ 1,493</u>	<u>\$ 1,665</u>	<u>\$ 518,650</u>

December 31, 2024

	<u>Not Past Due</u>	<u>1 to 30 Days</u>	<u>31 to 60 Days</u>	<u>61 to 150 Days</u>	<u>Over 151 Days</u>	<u>Total</u>
Expected credit loss rate	0-33.79%	0-100%	0-100%	0-100%	0-100%	
Gross carrying amount	\$ 539,688	\$ 8,228	\$ 5,144	\$ 12,992	\$ 15,092	\$ 581,144
Loss allowance	<u>(48)</u>	<u>(181)</u>	<u>(258)</u>	<u>(1,654)</u>	<u>(13,434)</u>	<u>(15,575)</u>
Amortized cost	<u>\$ 539,640</u>	<u>\$ 8,047</u>	<u>\$ 4,886</u>	<u>\$ 11,338</u>	<u>\$ 1,658</u>	<u>\$ 565,569</u>

September 30, 2024

	<u>Not Past Due</u>	<u>1 to 30 Days</u>	<u>31 to 60 Days</u>	<u>61 to 150 Days</u>	<u>Over 151 Days</u>	<u>Total</u>
Expected credit loss rate	0-29.56%	0-91.68%	0-93.23%	0-98.35%	0-100%	
Gross carrying amount	\$ 511,323	\$ 8,497	\$ 10,025	\$ 5,746	\$ 17,049	\$ 552,640
Loss allowance	<u>-</u>	<u>(99)</u>	<u>(312)</u>	<u>(602)</u>	<u>(12,104)</u>	<u>(13,117)</u>
Amortized cost	<u>\$ 511,323</u>	<u>\$ 8,398</u>	<u>\$ 9,713</u>	<u>\$ 5,144</u>	<u>\$ 4,945</u>	<u>\$ 539,523</u>

The movements of the loss allowance of trade receivables were as follows:

	<u>For the Nine Months Ended September 30</u>	
	<u>2025</u>	<u>2024</u>
Balance on January 1	\$ 15,575	\$ 12,997
Add: Net remeasurement of loss allowance	-	33
Less: Net remeasurement of loss allowance	(3,125)	-
Less: Amounts written off	(4)	-
Foreign exchange gains and losses	<u>(230)</u>	<u>87</u>
Balance on September 30	<u>\$ 12,216</u>	<u>\$ 13,117</u>

12. INVENTORIES

	<u>September 30, 2025</u>	<u>December 31, 2024</u>	<u>September 30, 2024</u>
Merchandise inventory	\$ 56,492	\$ 39,525	\$ 37,485
Consumables	<u>282,099</u>	<u>250,200</u>	<u>243,478</u>
	<u>\$ 338,591</u>	<u>\$ 289,725</u>	<u>\$ 280,963</u>

The cost of goods sold related to inventories for the three months ended September 30, 2025 and 2024 and for the nine months ended September 30, 2025 and 2024 was \$296,361 thousand, \$329,320 thousand, \$928,017 thousand and \$923,359 thousand, respectively.

The cost of goods sold related to inventories included (reversal of) write-down of inventory in the amounts of \$271 thousand, \$3,676 thousand, \$(21) thousand and \$9,274 thousand, respectively. Inventory write-downs were reversed as a result of increased selling prices in certain markets.

13. SUBSIDIARIES

a. Subsidiaries included in the consolidated financial statements

Investor	Investee	Nature of Activities	Proportion of Ownership (%)			Remark
			September 30, 2025	December 31, 2024	September 30, 2024	
Universal Vision Biotechnology Co., Ltd.	Taixue Investment Holdings Co., Ltd.	Investment	100.00	100.00	100.00	-
Taixue Investment Holdings Co., Ltd.	Taixue Jinghua Co., Ltd.	Wholesale and retail of medical equipment, western medicine	100.00	100.00	100.00	1)
Taixue Investment Holdings Co., Ltd.	Taixue Jhongdou Co., Ltd.	Wholesale and retail of medical equipment, western medicine	100.00	100.00	100.00	2)
Taixue Investment Holdings Co., Ltd.	Eyeseer Medical Inc.	Wholesale and retail of medical equipment	100.00	100.00	100.00	3)
Taixue Investment Holdings Co., Ltd.	Taixue Jhongke Co., Ltd.	Wholesale and retail of medical equipment, western medicine	16.67	16.67	16.67	4)
Taixue Investment Holdings Co., Ltd.	Taixue Chongde Co., Ltd.	Wholesale and retail of medical equipment	16.67	-	-	5)
Taixue Investment Holdings Co., Ltd.	Taixue Keelung Co., Ltd.	Wholesale and retail of medical equipment	16.67	-	-	6)
Universal Vision Biotechnology Co., Ltd.	Universal Group (BVI) Inc.	Investment	100.00	100.00	100.00	-
Universal Group (BVI) Inc.	Universal Group Holding Co., Ltd.	Investment	100.00	100.00	100.00	-
Universal Group Holding Co., Ltd.	Universal International (Samoa) Co., Ltd.	Investment	100.00	100.00	100.00	-
Universal International (Samoa) Co., Ltd.	Universal Vision Biotechnology (Shanghai) Co., Ltd.	Purchase and sale of ophthalmic surgical investments, medical optical instruments, etc.	100.00	100.00	100.00	-
Universal Vision Biotechnology (Shanghai) Co., Ltd.	Taixue (Jiangsu) Investment Co., Ltd.	Investment	100.00	100.00	100.00	-
Taixue (Jiangsu) Investment Co., Ltd.	Taixue Medical Investment Management (Zhejiang) Co., Ltd.	Enterprise and medical project investment	70.00	70.00	70.00	-
Taixue Medical Investment Management (Zhejiang) Co., Ltd.	Kunshan Universal Trading Co., Ltd.	Import and export of medical devices and related services	100.00	100.00	100.00	-
Taixue Medical Investment Management (Zhejiang) Co., Ltd.	Taixue (Jiangsu) Glasses Co., Ltd.	Wholesale and retail of glasses	100.00	100.00	100.00	-
Taixue Medical Investment Management (Zhejiang) Co., Ltd.	Ningbo Haishu Taixue Ophthalmic Outpatient Department Ltd.	Ophthalmology diagnosis and eyeglasses wholesale and retail	100.00	100.00	100.00	-
Taixue Medical Investment Management (Zhejiang) Co., Ltd.	Taixue (Jiangsu) Medical Investment Management Co., Ltd.	Enterprise and medical project investment management and consulting services	100.00	100.00	100.00	7)
Taixue Medical Investment Management (Zhejiang) Co., Ltd.	Taixue Dixin Medical Investment Management (Hangzhou) Co., Ltd.	Healthcare investment management	100.00	100.00	100.00	8)
Taixue Dixin Medical Investment Management (Hangzhou) Co., Ltd.	Hangzhou Taixue Ophthalmic Outpatient Department Ltd.	Ophthalmology diagnosis and eyeglasses wholesale and retail	100.00	100.00	100.00	-
Taixue (Jiangsu) Medical Investment Management Co., Ltd.	Suzhou Haiweishi Ophthalmic Clinic (LP)	The scope of ophthalmology and surgery is limited to outpatient surgery, and it also engages in spectacles and retail	80.00	80.00	80.00	9)
Taixue Dixin Medical Investment Management (Hangzhou) Co., Ltd.	Suzhou Haiweishi Ophthalmic Clinic (LP)	The scope of ophthalmology and surgery is limited to outpatient surgery, and it also engages in spectacles and retail	20.00	20.00	20.00	9)
Hangzhou Taixue Ophthalmic Outpatient Department Ltd.	Hangzhou Lingping Taixue Ophthalmic Hospital Ltd.	Retail, medical device sales and medical services	-	100.00	100.00	10)
Hangzhou Taixue Ophthalmic Outpatient Department Ltd.	Taixue (Hangzhou) Glasses Co., Ltd.	Wholesale and retail of glasses and sale of medical devices	100.00	100.00	100.00	11)
Hangzhou Taixue Ophthalmic Outpatient Department Ltd.	Hangzhou Taixue (II) Ophthalmic Outpatient Department Ltd.	Ophthalmic medical services and sale of medical devices	100.00	100.00	100.00	11)

1) Taixue Investment Holdings Co., Ltd. invested in Taixue Jinghua Co., Ltd. in 2020, and held 100,000 preferred shares A, \$10 per share, with 20 voting rights per share, or more than half (80%) of the voting rights; therefore, Taixue Jinghua Co., Ltd. is a controlled subsidiary of the Company. On December 15, 2023, Taixue Investment Holdings Co., Ltd. acquired 41.66% of the shares in Taixue Jinghua Co., Ltd., resulting in an increase of its shareholding from 16.67% to 58.33%. On January 19, 2024, Taixue Investment Holdings Co., Ltd. acquired 41.67% of the shares in Taixue Jinghua Co., Ltd., resulting in an increase of its shareholding from 58.33% to 100%. Taixue Jinghua Co., Ltd. was approved for dissolution by the sole director on February 27, 2025, and as of November 12, 2025, the related liquidation procedures are still in progress.

2) Taixue Investment Holdings Co., Ltd. invested in Taixue Jhongdou Co., Ltd. in 2022, and held 1,000,000 preferred shares A, \$1 per share, with 20 voting rights per share, or more than half (80%) of the voting rights; therefore, Taixue Jhongdou Co., Ltd. is a controlled subsidiary of the Company. On December 15, 2023, Taixue Investment Holdings Co., Ltd. acquired 41.66% of the shares in Taixue Jhongdou Co., Ltd., resulting in an increase of its shareholding from 16.67% to 58.33%. On January 19, 2024, Taixue Investment Holdings Co., Ltd. acquired 41.67% of the shares in Taixue Jhongdou Co., Ltd., resulting in an increase of its shareholding from 58.33% to 100%. Taixue Jhongdou Co., Ltd. was approved for dissolution by the sole director on February 27, 2025, and as of November 12, 2025, the related liquidation procedures are still in progress.

- 3) Taixue Investment Holdings Co., Ltd. has increased the capital of Eyeseer Medical Inc. by \$10,000 thousand in 2024, and further increased its capital by \$10,000 thousand in 2025.
- 4) Taixue Investment Holdings Co., Ltd. invested in Taixue Jhongke Co., Ltd. in 2023, and held 1,000,000 preferred shares A, \$1 per share, with 20 voting rights per share, or more than half (80%) of the voting rights; therefore, Taixue Jhongke Co., Ltd. is a controlled subsidiary of the Company.
- 5) Taixue Investment Holdings Co., Ltd. invested in Taixue Chongde Co., Ltd. in 2025, and held 1,000,000 preferred shares A, \$1 per share, with 20 voting rights per share, or more than half (80%) of the voting rights; therefore, Taixue Chongde Co., Ltd. is a controlled subsidiary of the Company.
- 6) Taixue Investment Holdings Co., Ltd. invested in Taixue Keelung Co., Ltd. in 2025, and held 1,000,000 preferred shares A, \$1 per share, with 20 voting rights per share, or more than half (80%) of the voting rights; therefore, Taixue Keelung Co., Ltd. is a controlled subsidiary of the Company.
- 7) Taixue Medical Investment Management (Zhejiang) Co., Ltd. has increased the capital of Taixue (Jiangsu) Medical Investment Management Co., Ltd. by RMB5,500 thousand in 2024, and further increased its capital by RMB1,500 thousand in 2025.
- 8) Taixue Medical Investment Management (Zhejiang) Co., Ltd. has increased the capital of Taixue Dixin Medical Investment Management (Hangzhou) Co., Ltd. by RMB200 thousand in 2025.
- 9) Taixue (Jiangsu) Medical Investment Management Co., Ltd. and Taixue Dixin Medical Investment Management (Hangzhou) Co., Ltd. invested RMB1,000 thousand and RMB250 thousand in Suzhou Haiweishi Ophthalmic Clinic (LP) in 2024, respectively, and RMB800 thousand and RMB200 thousand in Suzhou Haiweishi Ophthalmic Clinic (LP) in 2025, respectively.
- 10) Hangzhou Taixue Ophthalmic Outpatient Department Ltd. invested RMB5,000 thousand in Hangzhou Lingping Taixue Ophthalmic Hospital Ltd. in 2024. Hangzhou Lingping Taixue Ophthalmic Hospital Ltd. was approved for dissolution by the shareholders on February 14, 2025, and the deregistration was completed in August 2025.
- 11) Hangzhou Taixue Ophthalmic Outpatient Department Ltd. invested RMB1,000 thousand and RMB1,000 thousand in Taixue (Hangzhou) Glasses Co., Ltd. and Hangzhou Taixue (II) Ophthalmic Outpatient Department Ltd. in 2024, respectively.

b. Details of subsidiaries that have material non-controlling interests

Name of Subsidiary	Proportion of Ownership and Voting Rights Held by Non-controlling Interests		
	September 30, 2025	December 31, 2024	September 30, 2024
	Taixue Medical Investment Management (Zhejiang) Co., Ltd.	30%	30%

Refer to Note 35, Tables 4 and 5 for the information on the places of incorporation and principal place of business.

Name of Subsidiary	Profit (Loss) Allocated to Non-controlling Interests				Accounted Non-controlling Interests		
	For the Three Months Ended September 30		For the Nine Months Ended September 30		September 30,	December 31,	September 30,
	2025	2024	2025	2024	2025	2024	2024
Taixue Medical Investment Management (Zhejiang) Co., Ltd.	\$ 542	\$ (6,646)	\$ (729)	\$ (18,877)	\$ 106,187	\$ 113,793	\$ 124,378

Summarized financial information of the Group's subsidiary with material non-controlling interests is set out below. The summarized financial information below represents amounts before intragroup eliminations.

Taixue Medical Investment Management (Zhejiang) Co., Ltd. and its' subsidiaries

	<u>September 30, 2025</u>	<u>December 31, 2024</u>	<u>September 30, 2024</u>
Current assets	\$ 305,631	\$ 307,853	\$ 339,636
Non-current assets	201,094	280,457	310,071
Current liabilities	(132,633)	(162,016)	(182,996)
Non-current liabilities	<u>(20,137)</u>	<u>(46,985)</u>	<u>(52,118)</u>
Equity	<u>\$ 353,955</u>	<u>\$ 379,309</u>	<u>\$ 414,593</u>
Equity attributable to:			
Owners of Taixue Medical Investment Management (Zhejiang) Co., Ltd.	\$ 247,768	\$ 265,516	\$ 290,215
Non-controlling interests of Taixue Medical Investment Management (Zhejiang) Co., Ltd.	<u>106,187</u>	<u>113,793</u>	<u>124,378</u>
	<u>\$ 353,955</u>	<u>\$ 379,309</u>	<u>\$ 414,593</u>
	<u>For the Three Months Ended September 30</u>	<u>For the Nine Months Ended September 30</u>	
	<u>2025</u>	<u>2024</u>	<u>2025</u>
	<u>2024</u>	<u>2025</u>	<u>2024</u>
Revenue	<u>\$ 125,307</u>	<u>\$ 171,953</u>	<u>\$ 389,921</u>
Profit (loss) for the period	\$ 1,806	\$ (22,154)	\$ (2,431)
Other comprehensive income (loss) for the period	<u>15,660</u>	<u>(3,435)</u>	<u>(22,923)</u>
Total comprehensive income (loss) for the period	<u>\$ 17,466</u>	<u>\$ (25,589)</u>	<u>\$ (25,354)</u>
Profit (loss) attributable to:			
Owners of Taixue Medical Investment Management (Zhejiang) Co., Ltd.	\$ 1,264	\$ (15,508)	\$ (1,702)
Non-controlling interests of Taixue Medical Investment Management (Zhejiang) Co., Ltd.	<u>542</u>	<u>(6,646)</u>	<u>(729)</u>
	<u>\$ 1,806</u>	<u>\$ (22,154)</u>	<u>\$ (2,431)</u>

(Continued)

	For the Three Months Ended		For the Nine Months Ended	
	September 30		September 30	
	2025	2024	2025	2024
Total comprehensive income (loss) attributable to:				
Owners of Taixue Medical Investment Management (Zhejiang) Co., Ltd.	\$ 12,226	\$ (17,912)	\$ (17,748)	\$ (30,714)
Non-controlling interests of Taixue Medical Investment Management (Zhejiang) Co., Ltd.	<u>5,240</u>	<u>(7,677)</u>	<u>(7,606)</u>	<u>(13,163)</u>
	<u>\$ 17,466</u>	<u>\$ (25,589)</u>	<u>\$ (25,354)</u>	<u>\$ (43,877)</u>
Cash inflow (outflow) from:				
Operating activities			\$ 59,824	\$ 31,011
Investing activities			(24,440)	(2,157)
Financing activities			<u>(26,609)</u>	<u>13,882</u>
Net cash inflow			<u>\$ 8,775</u>	<u>\$ 42,736</u> (Concluded)

c. Subsidiaries excluded from the consolidated financial statements: None.

14. PROPERTY, PLANT AND EQUIPMENT

	September 30,	December 31,	September 30,					
	2025	2024	2024					
Assets used by the Group	<u>\$ 1,875,270</u>	<u>\$ 1,756,259</u>	<u>\$ 1,749,455</u>					
	Land	Buildings	Machine	Transport Equipment	Office Equipment	Leasehold Improvements	Unfinished Construction and Equipment Pending Acceptance	Total
Cost								
Balance on January 1, 2025	\$ 179,865	\$ 67,108	\$ 2,181,310	\$ 3,217	\$ 257,121	\$ 643,689	\$ 96,014	\$ 3,428,324
Additions	-	-	218,790	-	24,513	20,881	124,680	388,864
Disposals	-	-	(11,748)	-	(4,298)	(712)	-	(16,758)
Reclassified	-	-	-	-	4,076	38,139	(43,599)	(1,384)
Effect of foreign currency exchange differences	-	-	(22,624)	(111)	(1,025)	(7,645)	(42)	(31,447)
Balance on September 30, 2025	<u>\$ 179,865</u>	<u>\$ 67,108</u>	<u>\$ 2,365,728</u>	<u>\$ 3,106</u>	<u>\$ 280,387</u>	<u>\$ 694,352</u>	<u>\$ 177,053</u>	<u>\$ 3,767,599</u>
Accumulated depreciation								
Balance on January 1, 2025	\$ -	\$ 23,474	\$ 1,142,067	\$ 2,230	\$ 168,581	\$ 335,713	\$ -	\$ 1,672,065
Depreciation expense	-	973	165,431	291	29,841	61,087	-	257,623
Disposals	-	-	(11,575)	-	(4,031)	(476)	-	(16,082)
Effect of foreign currency exchange differences	-	-	(14,411)	(76)	(888)	(5,902)	-	(21,277)
Balance on September 30, 2025	<u>\$ -</u>	<u>\$ 24,447</u>	<u>\$ 1,281,512</u>	<u>\$ 2,445</u>	<u>\$ 193,503</u>	<u>\$ 390,422</u>	<u>\$ -</u>	<u>\$ 1,892,329</u>
Carrying amount on September 30, 2025	<u>\$ 179,865</u>	<u>\$ 42,661</u>	<u>\$ 1,084,216</u>	<u>\$ 661</u>	<u>\$ 86,884</u>	<u>\$ 303,930</u>	<u>\$ 177,053</u>	<u>\$ 1,875,270</u>
Carrying amount on December 31, 2024 and January 1, 2025	<u>\$ 179,865</u>	<u>\$ 43,634</u>	<u>\$ 1,039,243</u>	<u>\$ 987</u>	<u>\$ 88,540</u>	<u>\$ 307,976</u>	<u>\$ 96,014</u>	<u>\$ 1,756,259</u>

(Continued)

	<u>Land</u>	<u>Buildings</u>	<u>Machine</u>	<u>Transport Equipment</u>	<u>Office Equipment</u>	<u>Leasehold Improvements</u>	<u>Unfinished Construction and Equipment Pending Acceptance</u>	<u>Total</u>
<u>Cost</u>								
Balance on January 1, 2024	\$ 179,865	\$ 67,108	\$ 1,914,186	\$ 5,157	\$ 245,581	\$ 615,674	\$ 32,822	\$ 3,060,393
Additions	-	-	229,038	-	19,096	17,560	45,502	311,196
Disposals	-	-	(86,700)	(1,498)	(14,355)	(14,247)	-	(116,800)
Reclassified	-	-	92,755	-	3,007	28,301	(30,864)	93,199
Effect of foreign currency exchange differences	-	-	15,102	155	755	5,637	81	21,730
Balance on September 30, 2024	<u>\$ 179,865</u>	<u>\$ 67,108</u>	<u>\$ 2,164,381</u>	<u>\$ 3,814</u>	<u>\$ 254,084</u>	<u>\$ 652,925</u>	<u>\$ 47,541</u>	<u>\$ 3,369,718</u>
<u>Accumulated depreciation</u>								
Balance on January 1, 2024	\$ -	\$ 22,177	\$ 1,022,164	\$ 3,339	\$ 145,885	\$ 274,478	\$ -	\$ 1,468,043
Depreciation expense	-	973	152,311	451	28,932	68,439	-	251,106
Disposals	-	-	(86,616)	(1,498)	(13,624)	(9,486)	-	(111,224)
Effect of foreign currency exchange differences	-	-	8,293	104	598	3,343	-	12,338
Balance on September 30, 2024	<u>\$ -</u>	<u>\$ 23,150</u>	<u>\$ 1,096,152</u>	<u>\$ 2,396</u>	<u>\$ 161,791</u>	<u>\$ 336,774</u>	<u>\$ -</u>	<u>\$ 1,620,263</u>
Carrying amount on September 30, 2024	<u>\$ 179,865</u>	<u>\$ 43,958</u>	<u>\$ 1,068,229</u>	<u>\$ 1,418</u>	<u>\$ 92,293</u>	<u>\$ 316,151</u>	<u>\$ 47,541</u>	<u>\$ 1,749,455</u>

(Concluded)

No impairment loss or reversal of impairment loss was recognized for the nine months ended September 30, 2025 and 2024 as there was no indication of impairment.

The above items of property, plant and equipment are depreciated on a straight-line basis over the estimated useful lives as follows:

Building	
Main buildings	50 years
Decoration and partition works	3-6 years
Machine	3-11 years
Transport equipment	4-5 years
Office equipment	1-10 years
Leasehold improvements	Whichever is shorter, the lease term or useful term

Refer to Note 32 for property, plant and equipment used by the Group and pledged as collateral for bank borrowings.

15. LEASE ARRANGEMENTS

a. Right-of-use assets

	<u>September 30, 2025</u>	<u>December 31, 2024</u>	<u>September 30, 2024</u>
<u>Carrying amount</u>			
Buildings	\$ 925,987	\$ 907,954	\$ 847,684
Transportation equipment	<u>6,611</u>	<u>9,208</u>	<u>10,625</u>
	<u>\$ 932,598</u>	<u>\$ 917,162</u>	<u>\$ 858,309</u>

	For the Three Months Ended September 30		For the Nine Months Ended September 30	
	2025	2024	2025	2024
Additions to right-of-use assets			<u>\$ 162,614</u>	<u>\$ 263,645</u>
Depreciation charge for right-of-use assets				
Buildings	\$ 47,026	\$ 43,875	\$ 139,783	\$ 126,316
Transportation equipment	<u>1,333</u>	<u>1,417</u>	<u>4,067</u>	<u>4,102</u>
	<u>\$ 48,359</u>	<u>\$ 45,292</u>	<u>\$ 143,850</u>	<u>\$ 130,418</u>
Income from the subleasing of right-of-use assets (presented in operating revenue)	<u>\$ (54,446)</u>	<u>\$ (46,060)</u>	<u>\$ (153,503)</u>	<u>\$ (138,180)</u>

Except for the above addition and recognized depreciation, the Group did not have significant sublease or impairment of right-of-use assets during the nine months ended September 30, 2025 and 2024.

b. Lease liabilities

	September 30, 2025	December 31, 2024	September 30, 2024
<u>Carrying amount</u>			
Current	<u>\$ 184,636</u>	<u>\$ 178,399</u>	<u>\$ 177,682</u>
Non-current	<u>\$ 798,526</u>	<u>\$ 783,828</u>	<u>\$ 723,275</u>

Ranges of discount rates for lease liabilities were as follows:

	September 30, 2025	December 31, 2024	September 30, 2024
Buildings	1.195%-4.75%	1.195%-4.75%	1.195%-4.75%
Transportation equipment	1.94%-2.72%	1.195%-2.32%	1.195%-2.32%

c. Material leasing activities and terms

The Group leases buildings for use as offices and retail stores with lease terms of 3 to 15 years. Lease contracts for part of retail stores contain variable payments which are determined at a specific percentage of sales generated from the respective stores. The Group does not have bargain purchase options to acquire the leasehold buildings at the end of the lease term. In addition, the Group is prohibited from subleasing or transferring all or any portion of the underlying assets without the lessor's consent.

d. Subleases

The Group subleases its right-of-use assets for buildings under operating leases. The maturity analysis of lease payments receivable under operating subleases was as follows:

	<u>September 30, 2025</u>	<u>December 31, 2024</u>	<u>September 30, 2024</u>
Year 1	\$ 200,428	\$ 188,853	\$ 179,084
Year 2	67,690	106,337	122,279
Year 3	<u>40,559</u>	<u>15,162</u>	<u>2,721</u>
	<u>\$ 308,677</u>	<u>\$ 310,352</u>	<u>\$ 304,084</u>

e. Other lease information

	<u>For the Three Months Ended September 30</u>		<u>For the Nine Months Ended September 30</u>	
	<u>2025</u>	<u>2024</u>	<u>2025</u>	<u>2024</u>
Expenses relating to short-term leases	<u>\$ 1,315</u>	<u>\$ 1,743</u>	<u>\$ 4,191</u>	<u>\$ 4,985</u>
Expenses relating to low-value asset leases	<u>\$ 171</u>	<u>\$ 63</u>	<u>\$ 420</u>	<u>\$ 190</u>
Expenses relating to variable lease payments not included in the measurement of lease liabilities	<u>\$ 390</u>	<u>\$ 436</u>	<u>\$ 1,088</u>	<u>\$ 1,162</u>
Total cash outflow for leases			<u>\$ (157,425)</u>	<u>\$ (141,748)</u>

The Group's leases of certain buildings and office equipment qualify as short-term leases. The Group has elected to apply the recognition exemption and thus, did not recognize right-of-use assets and lease liabilities for these leases.

16. INTANGIBLE ASSETS

	<u>Computer Software</u>	<u>Other Intangible Assets</u>	<u>Total</u>
<u>Cost</u>			
Balance on January 1, 2025	\$ 32,448	\$ 16,899	\$ 49,347
Additions	1,124	-	1,124
Reclassified	1,384	-	1,384
Disposals	(409)	-	(409)
Effect of foreign currency exchange differences	<u>(226)</u>	<u>(1,024)</u>	<u>(1,250)</u>
Balance on September 30, 2025	<u>\$ 34,321</u>	<u>\$ 15,875</u>	<u>\$ 50,196</u>

(Continued)

	Computer Software	Other Intangible Assets	Total
<u>Accumulated amortization</u>			
Balance on January 1, 2025	\$ 26,557	\$ -	\$ 26,557
Amortization expense	1,865	-	1,865
Disposals	(393)	-	(393)
Effect of foreign currency exchange differences	<u>(126)</u>	<u>-</u>	<u>(126)</u>
Balance on September 30, 2025	<u>\$ 27,903</u>	<u>\$ -</u>	<u>\$ 27,903</u>
Carrying amount on September 30, 2025	<u>\$ 6,418</u>	<u>\$ 15,875</u>	<u>\$ 22,293</u>
Carrying amount on December 31, 2024 and January 1, 2025	<u>\$ 5,891</u>	<u>\$ 16,899</u>	<u>\$ 22,790</u>
<u>Cost</u>			
Balance on January 1, 2024	\$ 33,978	\$ 16,062	\$ 50,040
Additions	2,005	-	2,005
Disposals	(3,392)	-	(3,392)
Effect of foreign currency exchange differences	<u>218</u>	<u>673</u>	<u>891</u>
Balance on September 30, 2024	<u>\$ 32,809</u>	<u>\$ 16,735</u>	<u>\$ 49,544</u>
<u>Accumulated amortization</u>			
Balance on January 1, 2024	\$ 27,059	\$ -	\$ 27,059
Amortization expense	2,602	-	2,602
Disposals	(3,392)	-	(3,392)
Effect of foreign currency exchange differences	<u>84</u>	<u>-</u>	<u>84</u>
Balance on September 30, 2024	<u>\$ 26,353</u>	<u>\$ -</u>	<u>\$ 26,353</u>
Carrying amount on September 30, 2024	<u>\$ 6,456</u>	<u>\$ 16,735</u>	<u>\$ 23,191</u> (Concluded)

Other intangible assets are amortized on a straight-line basis over their estimated useful lives as follows:

Computer software	3-10 years
-------------------	------------

Other intangible assets

The Group acquired Suzhou Haiweishi Ophthalmic Clinic (LP) and recognized intangible assets which consisted of the expected benefits from obtaining the medical license approved by the government.

	For the Three Months Ended September 30		For the Nine Months Ended September 30	
	2025	2024	2025	2024
An analysis of amortization by function				
Operating costs	\$ 4	\$ 29	\$ 61	\$ 86
Selling and marketing expenses	50	217	343	644
General and administrative expenses	<u>479</u>	<u>488</u>	<u>1,461</u>	<u>1,872</u>
	<u>\$ 533</u>	<u>\$ 734</u>	<u>\$ 1,865</u>	<u>\$ 2,602</u>

17. BORROWINGS

Short-term borrowings

	September 30, 2025	December 31, 2024	September 30, 2024
<u>Secured borrowings</u> (Note 32)			
Bank loans	<u>\$ 100,000</u>	<u>\$ -</u>	<u>\$ -</u>
<u>Unsecured borrowings</u>			
Line of credit borrowings	<u>\$ 129,149</u>	<u>\$ 92,012</u>	<u>\$ 476,968</u>
Range of interest rate	1.875%-3.00%	1.91%-3.45%	1.90%-3.45%

18. TRADE PAYABLES

	September 30, 2025	December 31, 2024	September 30, 2024
<u>Trade payable</u>			
Operating	<u>\$ 245,260</u>	<u>\$ 268,070</u>	<u>\$ 269,141</u>

The Group's credit terms with suppliers are 30-90 days from the end of the month.

19. OTHER PAYABLES

	<u>September 30, 2025</u>	<u>December 31, 2024</u>	<u>September 30, 2024</u>
Payables for salaries or bonuses	\$ 108,818	\$ 117,415	\$ 123,030
Payables for remuneration of employees and directors	42,009	58,426	45,925
Payables for advertising fees	30,001	30,628	23,640
Payables for maintenance fees	15,021	15,128	11,466
Payables for professional service fees	6,086	4,245	21,832
Payables for commodity tax	6,729	15,628	8,688
Others	<u>26,685</u>	<u>35,983</u>	<u>28,890</u>
	<u>\$ 235,349</u>	<u>\$ 277,453</u>	<u>\$ 263,471</u>

20. PAYABLES FOR EQUIPMENT AND LONG-TERM ACCOUNTS PAYABLES

<u>Items</u>	<u>Period</u>	<u>September 30, 2025</u>	<u>December 31, 2024</u>	<u>September 30, 2024</u>	<u>Repayment Agreement</u>
Purchase of equipment	May 2019 - September 2029	\$ 190,152	\$ 161,988	\$ 181,472	Installment by contract
Less: Current portion		<u>(144,613)</u>	<u>(91,080)</u>	<u>(116,501)</u>	
		<u>\$ 45,539</u>	<u>\$ 70,908</u>	<u>\$ 64,971</u>	

Long-term payables include the Company's installments payable for purchase of equipment. The payment period ends in September 2029. The long-term payables due in future years are as follows:

<u>Payment Period</u>	<u>Amount</u>
2026.10.01-2027.09.30	\$ 28,559
2027.10.01-2028.09.30	12,763
2028.10.01-2029.09.30	<u>4,217</u>
	<u>\$ 45,539</u>

21. RETIREMENT BENEFIT PLANS

Defined Contribution Plans

The pension plan under the Labor Pension Act (LPA) for the Group's resident employees in the ROC is a government-managed defined contribution plan. Based on the LPA, the Company and its subsidiaries makes monthly contributions to employees' individual pension accounts at 6% of their monthly salaries.

The employees of the Group's subsidiary in China are members of a state-managed retirement benefit plan operated by the government of China. The subsidiary is required to contribute a specified percentage of payroll costs to the retirement benefit scheme to fund the benefits. The only obligation of the Group with respect to the retirement benefit plan is to make the specified contributions.

An analysis by function of the amount recognized in profit or loss in respect the defined contribution plans is as follows:

	For the Three Months Ended September 30		For the Nine Months Ended September 30	
	2025	2024	2025	2024
Operating expenses	\$ 4,093	\$ 3,674	\$ 12,058	\$ 10,823

22. EQUITY

a. Share capital

Ordinary shares

	September 30, 2025	December 31, 2024	September 30, 2024
Shares authorized (in thousands of shares)	200,000	200,000	200,000
Shares authorized	\$ 2,000,000	\$ 2,000,000	\$ 2,000,000
Shares issued and fully paid (in thousands of shares)	84,725	84,725	84,725
Shares issued	\$ 847,249	\$ 847,249	\$ 847,249

The ordinary shares have a par value of \$10 (in dollars). Holder of each share is entitled to one vote and right to dividend.

b. Capital surplus

	September 30, 2025	December 31, 2024	September 30, 2024
May be used to offset a deficit, distributed as cash dividends, or transferred to share capital*			
Issuance of ordinary shares	\$ 185,652	\$ 185,652	\$ 185,652
Consideration received over the carrying amount of issued convertible bonds	168,011	168,011	168,011
Treasury share transactions	1,829	1,829	1,829
Expired employee share options and conversion differences on exercised employee share options	26,432	26,432	26,432
	\$ 381,924	\$ 381,924	\$ 381,924

* Such capital surplus may be used to offset a deficit; when the Company has no deficit, such capital surplus may be distributed as cash dividends or transferred to share capital (limited to a certain percentage of the Company's capital surplus and to once a year).

c. Retained earnings and dividend policy

Under the dividends policy as set forth in the Articles, where the Company made a profit in a fiscal year, the profit shall be first utilized for paying taxes, offsetting losses of previous years, setting aside as legal reserve 10% of the remaining profit in accordance with the laws and regulations until the amount of legal reserve is equivalent to the paid-in capital, setting aside or reversing special reserve in accordance with the laws and regulations, and then any remaining profit together with any undistributed retained earnings shall be used by the Company's board of directors as the basis for proposing a distribution plan, which should be resolved in the shareholders' meeting for the distribution of dividends and bonuses to shareholders.

If the company distributes dividends and bonuses or all or part of the legal reserve and capital reserve in the form of cash distribution, the Company's board of directors is authorized to do so with the presence of more than two-thirds of the directors and the consent of more than half of the directors present and report to the shareholders meeting. For the policies on the distribution of compensation of employees and remuneration of directors, refer to compensation of employees and remuneration of directors in Note 24-g.

The Company is currently in the growing stage. The Company shall consider meeting future capital demand for business operations and its long-term financial plan, as well as satisfying the shareholders' demand for cash inflow, when deciding to distribute dividends. The Company's Articles of Incorporation provide that shareholders' dividends may be distributed in the form of shares or cash where cash dividends to be distributed may not be less than 30% of total dividends distributed.

Appropriations of earnings to the legal reserve shall be made until the legal reserve equals the Company's paid-in capital. The legal reserve may be used to offset deficit. If the Company has no deficit and the legal reserve has exceeded 25% of the Company's paid-in capital, the excess may be transferred to capital or distributed in cash.

The Company in accordance with the law when a special reserve is appropriated for cumulative net increases in fair value measurement of investment properties from prior period and cumulative net debit balance reserves from prior period, the sum of net profit for current period and items other than net profit that are included directly in the unappropriated earnings for current period is used if the prior unappropriated earnings are not sufficient.

The appropriations of earnings for 2024 and 2023 were as follows:

	Appropriation of Earnings	
	For the Year Ended December 31	
	2024	2023
Legal reserve	<u>\$ 102,156</u>	<u>\$ 100,009</u>
Special (reverse) reserve	<u>\$ (11,384)</u>	<u>\$ 6,342</u>
Cash dividends	<u>\$ 635,437</u>	<u>\$ 593,074</u>
Cash dividends per share (NT\$)	\$ 7.50	\$ 7.00

The above 2024 and 2023 appropriations for cash dividends were resolved by the Company's board of directors on March 6, 2025 and March 13, 2024, respectively; the other proposed appropriations were resolved by the shareholders in their meeting on May 26, 2025 and June 19, 2024, respectively.

d. Special reserve

	For the Nine Months Ended September 30	
	2025	2024
Balance on January 1	\$ 11,384	\$ 5,042
Appropriations in respect of		
Debits to other equity items	-	6,342
Reversals		
Reversal of the debits to other equity items	<u>(11,384)</u>	<u>-</u>
Balance on September 30	<u>\$ -</u>	<u>\$ 11,384</u>

e. Other equity items

1) Exchange differences on translating the financial statements of foreign operations

	For the Nine Months Ended September 30	
	2025	2024
Balance on January 1	\$ 7,352	\$ (11,384)
Recognized for the period		
Exchange differences on the translation of the financial statements of foreign operations	(25,397)	19,344
Relevant income taxes benefit (expense)	<u>5,080</u>	<u>(3,868)</u>
Balance on September 30	<u>\$ (12,965)</u>	<u>\$ 4,092</u>

2) Unrealized valuation loss on financial assets at FVTOCI

	For the Nine Months Ended September 30	
	2025	2024
Balance on January 1	\$ (2,847)	\$ -
Recognized for the period		
Unrealized gain - debt instruments	1,783	6,323
Unrealized gain - equity instruments	457	-
Relevant income taxes expense	<u>(357)</u>	<u>(1,265)</u>
Balance on September 30	<u>\$ (964)</u>	<u>\$ 5,058</u>

f. Non-controlling interests

	For the Nine Months Ended September 30	
	2025	2024
Balance on January 1	\$ 133,715	\$ 165,333
Non-controlling interest arising from acquisition of Taixue Chongde Co., Ltd.	5,000	-
Non-controlling interest arising from acquisition of Taixue Keelung Co., Ltd.	5,000	-
Non-controlling interest disposal of Taixue Jinghua Co., Ltd. and Taixue Jhongdou Co., Ltd. (Note 27)	-	(23,935)
Share in profit (loss) for the period	14,222	(8,317)
Other comprehensive (loss) income during the period		
Exchange difference on translating the financial statements of foreign entities	<u>(6,877)</u>	<u>5,714</u>
Balance on September 30	<u>\$ 151,060</u>	<u>\$ 138,795</u>

23. REVENUE

	For the Three Months Ended September 30		For the Nine Months Ended September 30	
	2025	2024	2025	2024
Revenue from contracts with customers				
Sale of goods	\$ 304,565	\$ 280,182	\$ 810,839	\$ 741,189
Brand licensing and technical services	473,713	600,934	1,637,947	1,811,541
Medical consumables	158,095	141,774	474,883	428,523
Consultancy services	<u>33,920</u>	<u>9,777</u>	<u>93,731</u>	<u>68,183</u>
	970,293	1,032,667	3,017,400	3,049,436
Rental income	<u>54,446</u>	<u>46,917</u>	<u>153,503</u>	<u>140,751</u>
	<u>\$ 1,024,739</u>	<u>\$ 1,079,584</u>	<u>\$ 3,170,903</u>	<u>\$ 3,190,187</u>

For descriptions of contracts with customers, please refer to Note 23 of the consolidated financial statements for the year ended December 31, 2024.

a. Contract balances

	September 30, 2025	December 31, 2024	September 30, 2024	January 1, 2024
Trade receivables (Note 11)	<u>\$ 518,650</u>	<u>\$ 565,569</u>	<u>\$ 539,523</u>	<u>\$ 584,252</u>
Contract liabilities (presented in other current liabilities)				
Sale of goods	<u>\$ 44,597</u>	<u>\$ 25,117</u>	<u>\$ 35,862</u>	<u>\$ 24,185</u>

b. Disaggregation of revenue, please refer to Note 36.

24. NET PROFIT FROM CONTINUING OPERATIONS

a. Interest income

	For the Three Months Ended September 30		For the Nine Months Ended September 30	
	2025	2024	2025	2024
Bank deposits	\$ 1,101	\$ 2,425	\$ 5,069	\$ 12,730
Financial assets at FVTPL	13,161	5,787	42,187	5,787
Investments in debt instruments at FVTOCI	1,203	1,108	3,719	1,490
Others	<u>147</u>	<u>133</u>	<u>435</u>	<u>377</u>
	<u>\$ 15,612</u>	<u>\$ 9,453</u>	<u>\$ 51,410</u>	<u>\$ 20,384</u>

b. Other income

	For the Three Months Ended September 30		For the Nine Months Ended September 30	
	2025	2024	2025	2024
Rental income	\$ 799	\$ 742	\$ 2,398	\$ 2,226
Others	<u>622</u>	<u>371</u>	<u>4,217</u>	<u>3,404</u>
	<u>\$ 1,421</u>	<u>\$ 1,113</u>	<u>\$ 6,615</u>	<u>\$ 5,630</u>

c. Other gains and losses

	For the Three Months Ended September 30		For the Nine Months Ended September 30	
	2025	2024	2025	2024
Loss on disposal of property, plant and equipment	\$ (506)	\$ (4,778)	\$ (562)	\$ (4,989)
Loss on disposal of intangible assets	-	-	(16)	-
Valuation gain (loss) of financial assets at FVTPL	83,281	(12,300)	(79,021)	(12,300)
Net foreign exchange gains (losses)	4,771	(3,233)	(9,646)	3,184
Gain from lease modifications	-	572	-	572
Others	<u>(449)</u>	<u>(777)</u>	<u>(628)</u>	<u>(1,365)</u>
	<u>\$ 87,097</u>	<u>\$ (20,516)</u>	<u>\$ (89,873)</u>	<u>\$ (14,898)</u>

d. Finance costs

	For the Three Months Ended September 30		For the Nine Months Ended September 30	
	2025	2024	2025	2024
Interest on bank loans	\$ 1,439	\$ 851	\$ 4,237	\$ 2,398
Interest on lease liabilities	4,869	4,169	14,352	11,451
Others	<u>2</u>	<u>2</u>	<u>7</u>	<u>6</u>
	<u>\$ 6,310</u>	<u>\$ 5,022</u>	<u>\$ 18,596</u>	<u>\$ 13,855</u>

e. Depreciation and amortization

	For the Three Months Ended September 30		For the Nine Months Ended September 30	
	2025	2024	2025	2024
An analysis of depreciation by function				
Operating costs	\$ 100,610	\$ 91,136	\$ 296,162	\$ 262,147
Operating expenses	<u>34,777</u>	<u>46,650</u>	<u>105,311</u>	<u>119,377</u>
	<u>\$ 135,387</u>	<u>\$ 137,786</u>	<u>\$ 401,473</u>	<u>\$ 381,524</u>
An analysis of amortization by function				
Operating costs	\$ 4	\$ 29	\$ 61	\$ 86
Operating expenses	<u>529</u>	<u>705</u>	<u>1,804</u>	<u>2,516</u>
	<u>\$ 533</u>	<u>\$ 734</u>	<u>\$ 1,865</u>	<u>\$ 2,602</u>

For information on the amortization of intangible assets allocated to individual line items, please refer to Note 16.

f. Employee benefits expense

	For the Three Months Ended September 30		For the Nine Months Ended September 30	
	2025	2024	2025	2024
Short-term benefits	\$ 166,787	\$ 174,790	\$ 486,944	\$ 519,438
Post-employment benefits (Note 21)				
Defined contribution plan	<u>4,093</u>	<u>3,674</u>	<u>12,058</u>	<u>10,823</u>
Total employee benefits expense	<u>\$ 170,880</u>	<u>\$ 178,464</u>	<u>\$ 499,002</u>	<u>\$ 530,261</u>
An analysis of employee benefits expense by function				
Operating costs	\$ 5,322	\$ 8,951	\$ 18,060	\$ 28,828
Operating expenses	<u>165,558</u>	<u>169,513</u>	<u>480,942</u>	<u>501,433</u>
	<u>\$ 170,880</u>	<u>\$ 178,464</u>	<u>\$ 499,002</u>	<u>\$ 530,261</u>

g. Compensation of employees and remuneration of directors and supervisors

According to the Company's Articles, the Company accrues compensation of employees and remuneration of directors at the rates of 1% to 10% Of which no less than 10% shall be allocated as compensation distributions for non-executive employees, and accrues remuneration of directors at rates of no higher than 3%, of net profit before income tax, compensation of employees, and remuneration of directors. However, if the Company has accumulated deficits, such deficits shall first be offset. Compensation of employees may be distributed in the form of shares or cash, and the recipients of such shares or cash may include employees of the Company's subsidiaries who meet certain qualifications.

The compensation of employees (including non-executive employees) and the remuneration of directors for the three months ended September 30, 2025 and 2024 and for the nine months ended September 30, 2025 and 2024 are as follows:

Amount

	For the Three Months Ended September 30		For the Nine Months Ended September 30	
	2025	2024	2025	2024
Compensation of employees	<u>\$ 12,661</u>	<u>\$ 9,499</u>	<u>\$ 30,370</u>	<u>\$ 32,193</u>
Remuneration of directors	<u>\$ 5,148</u>	<u>\$ 3,922</u>	<u>\$ 11,639</u>	<u>\$ 13,732</u>

If there is a change in the amounts after the annual consolidated financial statements are authorized for issue, the differences are recorded as a change in the accounting estimate.

The compensation of employees and remuneration of directors for 2024 and 2023 that were resolved by the board of directors on March 6, 2025 and March 13, 2024, respectively, are as show below:

	For the Year Ended December 31	
	2024	2023
	Cash	Cash
Compensation of employees	\$ 41,315	\$ 40,390
Remuneration of directors	17,111	20,195

There was no difference between the actual amounts of compensation of employees and remuneration of directors paid and the amounts recognized in the consolidated financial statements for the years ended December 31, 2024 and 2023.

Information on the compensation of employees and remuneration of directors resolved by the Company's board of directors is available at the Market Observation Post System website.

25. INCOME TAXES RELATING TO CONTINUING OPERATIONS

a. Income tax recognized in profit or loss

Major components of income tax expense are as follows:

	For the Three Months Ended September 30		For the Nine Months Ended September 30	
	2025	2024	2025	2024
Current tax				
In respect of the current period	\$ 63,786	\$ 67,713	\$ 214,474	\$ 215,117
Income tax on unappropriated earnings	(3,469)	(1,818)	11,567	11,236
Adjustments for prior year	<u>390</u>	<u>3,334</u>	<u>1,332</u>	<u>(9,010)</u>
	60,707	69,229	227,373	217,343
Deferred tax				
In respect of the current period	<u>2,590</u>	<u>(4,345)</u>	<u>1,669</u>	<u>(7,196)</u>
Income tax expense recognized in profit or loss	<u>\$ 63,297</u>	<u>\$ 64,884</u>	<u>\$ 229,042</u>	<u>\$ 210,147</u>

Applicable tax rate in Taiwan is 20%. Applicable tax rate for the subsidiaries in mainland China is 25%. Taxes in other jurisdictions shall be calculated at the applicable tax rates in relevant jurisdictions.

b. Income tax recognized in other comprehensive income

	For the Three Months Ended September 30		For the Nine Months Ended September 30	
	2025	2024	2025	2024
<u>Deferred tax</u>				
In respect of the current period:				
Translation of foreign operations	\$ 3,478	\$ (732)	\$ (5,080)	\$ 3,868
Unrealized gain on financial assets at FVTOCI	<u>326</u>	<u>1,292</u>	<u>357</u>	<u>1,265</u>
Total income tax recognized in other comprehensive income	<u>\$ 3,804</u>	<u>\$ 560</u>	<u>\$ (4,723)</u>	<u>\$ 5,133</u>

c. Income tax assessments

The income tax returns through 2023 of the Company, Taixue Investment Holding Co., Ltd., Taixue Jinghua Co., Ltd., Taixue Jhongdou Co., Ltd., Eyeseer Medical Inc. and Taixue Jhongke Co., Ltd., respectively, in Taiwan have been assessed by Taiwan's tax authorities. All other companies prepare their tax returns according to local law.

26. EARNINGS PER SHARE

Unit: NT\$ Per Share

	For the Three Months Ended September 30		For the Nine Months Ended September 30	
	2025	2024	2025	2024
Basic earnings per share	\$ 4.05	\$ 2.88	\$ 8.83	\$ 9.75
Diluted earnings per share	\$ 4.04	\$ 2.87	\$ 8.81	\$ 9.73

The earning and weighted average number of ordinary shares outstanding used in the computation of earnings per share were as follows:

Net Profit for the Period

	For the Three Months Ended September 30		For the Nine Months Ended September 30	
	2025	2024	2025	2024
Profit for the year attributable to owners of the Company	\$ 343,205	\$ 243,654	\$ 748,361	\$ 825,678
Effect of potentially dilutive ordinary shares:				
Compensation of employees	-	-	-	-
Earnings used in the computation of diluted earnings per share	\$ 343,205	\$ 243,654	\$ 748,361	\$ 825,678

The weighted average number of ordinary shares outstanding (in thousands of shares) was as follows:

	For the Three Months Ended September 30		For the Nine Months Ended September 30	
	2025	2024	2025	2024
Weighted average number of ordinary shares used in the computation of basic earnings per share	84,725	84,725	84,725	84,725
Effect of potentially dilutive ordinary shares:				
Compensation of employees	191	125	234	162
Weighted average number of ordinary shares used in the computation of diluted earnings per share	84,916	84,850	84,959	84,887

If the Group offered to settle compensation paid to employees in cash or shares, the Group assumed that the entire amount of the compensation will be settled in shares, and the resulting potential shares were included in the weighted average number of shares outstanding used in the computation of diluted earnings per share, as the effect is dilutive. Such dilutive effect of the potential shares is included in the computation of diluted earnings per share until the number of shares to be distributed to employees is resolved in the following year.

27. EQUITY TRANSACTIONS WITH NON-CONTROLLING INTERESTS

On January 19, 2024, the Group purchased 41.67% of the shares in Taixue Jinghua Co., Ltd. and Taixue Jhongdou Co., Ltd., increasing its interest from 58.33% to 100%.

The above transactions were accounted as equity transactions, since the Group did not cease to have control over these subsidiaries.

	<u>Taixue Jinghua Co., Ltd.</u>	<u>Taixue Jhongdou Co., Ltd.</u>	
Consideration paid	\$ (35,000)	\$ (32,100)	
The proportionate share of the carrying amount of the net assets of the subsidiary transferred to non-controlling interests	<u>9,190</u>	<u>14,745</u>	
Equity transaction difference	<u>\$ (25,810)</u>	<u>\$ (17,355)</u>	
	<u>Taixue Jinghua Co., Ltd.</u>	<u>Taixue Jhongdou Co., Ltd.</u>	<u>Total</u>
<u>Line items adjusted for equity transactions</u>			
Unappropriated earnings	<u>\$ 25,810</u>	<u>\$ 17,355</u>	<u>\$ 43,165</u>

28. CASH FLOW INFORMATION

The Group's operating, investing and financing activities with only partial cash receipts and payment for the nine months ended September 30, 2025 and 2024 were as follows:

a. Non-cash transactions

1) Purchase of property, plant and equipment

	For the Nine Months Ended September 30	
	<u>2025</u>	<u>2024</u>
Increase in property, plant and equipment	\$ 388,864	\$ 311,196
Add: Payables for equipment and long-term accounts payable at the beginning of the period	161,988	185,610
Less: Payables for equipment and long-term accounts payable at the end of the period	(190,152)	(181,472)
Purchase taxes	<u>-</u>	<u>(167)</u>
Cash payments	<u>\$ 360,700</u>	<u>\$ 315,167</u>

2) Interest received

	For the Nine Months Ended September 30	
	2025	2024
Interest income	\$ 51,410	\$ 20,384
Add: Interest receivable at the beginning of the period	9,220	1,188
Bonds premium amortization	64	23
Less: Interest receivable at the end of the period	(8,590)	(8,804)
Imputed interest on security deposits	<u>(428)</u>	<u>(371)</u>
Interest income received	<u>\$ 51,676</u>	<u>\$ 12,420</u>

3) Interest paid

	For the Nine Months Ended September 30	
	2025	2024
Interest expenses	\$ 18,596	\$ 13,855
Add: Interest payable at the beginning of the period	44	72
Less: Interest payable at the end of the period	(98)	(343)
Interest expense on lease liabilities	<u>(14,352)</u>	<u>(11,451)</u>
Interest expense paid	<u>\$ 4,190</u>	<u>\$ 2,133</u>

b. Changes in liabilities arising from financing activities

For the nine months ended September 30, 2025

	Opening Balance	Cash Flows	Non-cash Changes		Closing Balance
			New Leases	Others	
Short-term borrowings	\$ 92,012	\$ 139,675	\$ -	\$ (2,538)	\$ 229,149
Guarantee deposits received	584	-	-	-	584
Lease liabilities	<u>962,227</u>	<u>(151,726)</u>	<u>162,111</u>	<u>10,550</u>	<u>983,162</u>
	<u>\$ 1,054,823</u>	<u>\$ (12,051)</u>	<u>\$ 162,111</u>	<u>\$ 8,012</u>	<u>\$ 1,212,895</u>

For the nine months ended September 30, 2024

	Opening Balance	Cash Flows	Non-cash Changes		Closing Balance
			New Leases	Others	
Short-term borrowings	\$ 8,670	\$ 467,838	\$ -	\$ 460	\$ 476,968
Long-term borrowings	1,301	(1,352)	-	51	-
Guarantee deposits received	543	-	-	1	544
Lease liabilities	<u>768,290</u>	<u>(135,411)</u>	<u>262,834</u>	<u>5,244</u>	<u>900,957</u>
	<u>\$ 778,804</u>	<u>\$ 331,075</u>	<u>\$ 262,834</u>	<u>\$ 5,756</u>	<u>\$ 1,378,469</u>

29. CAPITAL MANAGEMENT

The Group manages its capital to ensure that entities in the Group will be able to continue as going concerns while maximizing the return to shareholders through the optimization of the debt and equity balance.

The capital structure of the Group consists of net debt (borrowings offset by cash and cash equivalents) and equity of the Group (comprising issued capital, reserves, retained earnings, other equity and non-controlling interests).

The Group is not subject to any externally imposed capital requirements.

30. FINANCIAL INSTRUMENTS

a. Fair value of financial instruments that are not measured at fair value

The management of the Group considers that the carrying amount of the financial assets and liabilities not measured at fair value approximated the fair value.

b. Fair value of financial instruments that are measured at fair value

Fair value hierarchy

September 30, 2025

	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Financial assets at FVTPL				
Mutual funds	<u>\$ 1,216,352</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 1,216,352</u>
Financial assets at FVTOCI				
Investments in equity instruments				
Domestic listed stocks	\$ 1,305	\$ -	\$ -	\$ 1,305
Investments in debt instruments				
Overseas government bonds	<u>104,614</u>	<u>-</u>	<u>-</u>	<u>104,614</u>
	<u>\$ 105,919</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 105,919</u>

December 31, 2024

	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Financial assets at FVTPL				
Mutual funds	<u>\$ 1,295,373</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 1,295,373</u>
Financial assets at FVTOCI				
Investments in debt instruments				
Overseas government bonds	<u>\$ 111,073</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 111,073</u>

September 30, 2024

	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Financial assets at FVTPL				
Mutual funds	\$ <u>1,284,206</u>	\$ <u> -</u>	\$ <u> -</u>	\$ <u>1,284,206</u>
Financial assets at FVTOCI				
Investments in debt instruments				
Overseas government bonds	\$ <u>117,007</u>	\$ <u> -</u>	\$ <u> -</u>	\$ <u>117,007</u>

c. Categories of financial instruments

	<u>September 30, 2025</u>	<u>December 31, 2024</u>	<u>September 30, 2024</u>
<u>Financial assets</u>			
Amortized cost (Note 1)	\$ 1,294,808	\$ 1,239,185	\$ 1,375,331
Financial assets at FVTPL			
Mandatorily classified as at FVTPL	1,216,352	1,295,373	1,284,206
Financial assets at FVTOCI			
Equity instruments	1,305	-	-
Debt instruments	104,614	111,073	117,007
<u>Financial liabilities</u>			
Amortized cost (Note 2)	900,494	800,107	1,191,596

Note 1: The balances include financial assets measured at amortized cost, which comprise cash and cash equivalents, trade receivables, other receivables, refundable deposits and other non-current assets.

Note 2: The balances include financial liabilities measured at amortized cost, which comprise short-term borrowings, trade payable, payables for equipment, other payable, long-term accounts payable and guarantee deposits.

d. Financial risk management objectives and policies

The Group's major financial instruments included equity and debt instrument investments, trade receivables, trade payables, borrowings and lease liabilities. The Group's corporate treasury function provides services to the business, coordinates access to domestic and international financial markets, and monitors and manages the financial risks relating to the operations of the Group through internal risk reports which analyze exposures by degree and magnitude of risks. These risks include market risk (including foreign currency risk, interest rate risk and other price risks), credit risk and liquidity risk.

1) Market risk

The Group's activities exposed it primarily to the financial risks of changes in foreign currency exchange rates (see (a) below), interest rates (see (b) below) and other price risks (see (c) below).

a) Foreign currency risk

The carrying amounts of the Group's foreign currency denominated monetary assets and monetary liabilities (including those eliminated on consolidation) at the end of the reporting period are set out in Note 34.

Sensitivity analysis

The Group is mainly exposed to the USD.

The following table details the Group's sensitivity to a 1% increase and decrease in the New Taiwan dollar (i.e., the functional currency) against the relevant foreign currencies. The sensitivity rate used when reporting foreign currency risk internally to key management personnel and representing management's assessment of the reasonably possible change in foreign exchange rates is 1%. The sensitivity analysis included only outstanding foreign currency denominated monetary items and adjusts their translation at the end of the year for a 1% change in foreign currency rates. A positive number below indicates a decrease in pre-tax profit and other equity associated with the New Taiwan dollar strengthening 1% against the relevant currency. For a 1% weakening of the New Taiwan dollar against the relevant currency, there would be an equal and opposite impact on pre-tax profit and other equity, and the balances below would be negative.

	USD Impact	
	For the Nine Months Ended	
	September 30	
	2025	2024
Profit or loss	\$ 1,273*	\$ 1,381*

* The result was mainly attributable to the exposure on outstanding deposits in USD and U.S. treasury bonds that were not hedged at the end of the reporting period.

b) Interest rate risk

The Group is exposed to interest rate risk because entities in the Group borrow funds and hold deposits at both fixed and floating interest rates. The risk is managed by the Group by maintaining an appropriate mix of fixed and floating rate borrowings.

The carrying amounts of the Group's financial assets and financial liabilities with exposure to interest rates at the end of the reporting period were as follows.

	September 30, 2025	December 31, 2024	September 30, 2024
Fair value interest rate risk			
Financial assets	\$ 314,792	\$ 297,657	\$ 367,283
Cash flow interest rate risk			
Financial assets	515,108	435,622	536,408
Financial liabilities	229,149	92,012	476,968

Sensitivity analysis

The sensitivity analysis below was determined based on the Group's exposure to interest rates for non-derivative instruments at the end of the reporting period. For floating rate assets and liabilities, the analysis was prepared assuming the amount of each liability outstanding at the end of the reporting period was outstanding for the whole year. A 0.1% increase or decrease is used when reporting interest rate risk internally to key management personnel and represents management's assessment of the reasonably possible change in interest rates.

If interest rates had been 0.1% higher and all other variables were held constant, the Group's pre-tax profit for the nine months ended September 30, 2025 and 2024 would have increased by \$214 thousand and \$45 thousand, respectively.

c) Other price risks

The Group was exposed to equity price risk through its investments in funds, beneficiary certificates and investments in domestic listed ordinary shares. The Group's equity price risk is mainly concentrated in equity instruments that are from investments classified as financial assets measured at fair value through profit or loss and investments in financial assets at fair value through other comprehensive income. If the prices of the above investments decrease by 1% as of the reporting period end date, the Group net income for the nine months ended September 30, 2025 and 2024, would decrease by \$12,164 thousand and \$12,842 thousand, respectively, and comprehensive income for the nine months ended September 30, 2025 and 2024, would decrease by \$12,177 thousand and \$12,842 thousand, respectively.

2) Credit risk

Credit risk refers to the risk that a counterparty will default on its contractual obligations resulting in a financial loss to the Group. At the end of the reporting period, the Group's maximum exposure to credit risk, which would cause a financial loss to the Group due to the failure of the counterparty to discharge its obligation and due to the financial guarantees provided by the Group, could be equal to the total of the carrying amount of the respective recognized financial assets as stated in the balance sheets.

In addition, the Group would review the recoverable amount of each receivable one by one at the end of the reporting period to ensure that impairment loss is recognized for unrecoverable receivables. As such, the Group's management concludes that the credit risk has been significantly reduced.

The important financial activities of the Group are reviewed by the board of directors in accordance with relevant rules and internal control systems. The Group follows the relevant financial and operating procedures for the overall financial risk management and segregation of responsibility.

3) Liquidity risk

The Group manages liquidity risk by monitoring and maintaining a level of cash and cash equivalents deemed adequate to finance the Group's operations and mitigate the effects of fluctuations in cash flows. In addition, management monitors the utilization of bank borrowings and ensures compliance with loan covenants.

Ultimate responsibility for liquidity risk management rests with the board of directors, which has built an appropriate liquidity risk management framework for the Group's short-, medium- and long-term funding and liquidity management requirements. The Group manages liquidity risk by maintaining adequate reserves, banking facilities and reserve borrowing facilities, and continuously monitoring forecasted and actual cash flows as well as matching the maturity profiles of financial assets and liabilities. As of September 30, 2025, December 31, 2024 and September 30, 2024, the Group had available unutilized short-term bank loan facilities set out in (b) below.

a) Liquidity and interest rate risk tables for non-derivative financial liabilities

The following tables detail the Group's remaining contractual maturities for its non-derivative financial liabilities with agreed repayment periods. The table have been drawn up based on the undiscounted cash flows of financial liabilities from the earliest date on which the Group can be required to pay. The tables include both interest and principal cash flows. Specifically, bank loans with a repayment on demand clause were included in the earliest time band regardless of

the probability of the banks choosing to exercise their rights. The maturity dates for other non-derivative financial liabilities were based on the agreed repayment dates.

To the extent that interest flows are floating rate, the undiscounted amount was derived from the average interest rate at the end of the reporting period.

September 30, 2025

	<u>Less than 1 Year</u>	<u>1-2 Years</u>	<u>2-5 Years</u>	<u>5-10 Years</u>	<u>10-15 Years</u>
Non-interest bearing					
Accounts payable	\$ 245,260	\$ -	\$ -	\$ -	\$ -
Payables on equipment	144,613	-	-	-	-
Long-term accounts payable	-	28,559	16,980	-	-
Guarantee deposits	584	-	-	-	-
Lease liabilities	202,649	161,192	383,217	300,639	12,716
Fixed interest rate liabilities					
Short-term borrowings	<u>230,109</u>	-	-	-	-
	<u>\$ 823,215</u>	<u>\$ 189,751</u>	<u>\$ 400,197</u>	<u>\$ 300,639</u>	<u>\$ 12,716</u>

December 31, 2024

	<u>Less than 1 Year</u>	<u>1-2 Years</u>	<u>2-5 Years</u>	<u>5-10 Years</u>	<u>10-15 Years</u>
Non-interest bearing					
Accounts payable	\$ 268,070	\$ -	\$ -	\$ -	\$ -
Payables on equipment	91,080	-	-	-	-
Long-term accounts payable	-	32,757	38,151	-	-
Guarantee deposits	584	-	-	-	-
Lease liabilities	195,229	178,044	350,533	278,816	30,143
Fixed interest rate liabilities					
Short-term borrowings	<u>92,857</u>	-	-	-	-
	<u>\$ 647,820</u>	<u>\$ 210,801</u>	<u>\$ 388,684</u>	<u>\$ 278,816</u>	<u>\$ 30,143</u>

September 30, 2024

	<u>Less than 1 Year</u>	<u>1-2 Years</u>	<u>2-5 Years</u>	<u>5-10 Years</u>	<u>10-15 Years</u>
Non-interest bearing					
Accounts payable	\$ 269,141	\$ -	\$ -	\$ -	\$ -
Payables on equipment	116,501	-	-	-	-
Long-term accounts payable	-	30,638	34,333	-	-
Guarantee deposits	544	-	-	-	-
Lease liabilities	192,647	170,833	330,805	234,878	31,018
Fixed interest rate liabilities					
Short-term borrowings	<u>479,384</u>	-	-	-	-
	<u>\$ 1,058,217</u>	<u>\$ 201,471</u>	<u>\$ 365,138</u>	<u>\$ 234,878</u>	<u>\$ 31,018</u>

b) Financing facilities

	<u>September 30, 2025</u>	<u>December 31, 2024</u>	<u>September 30, 2024</u>
Unsecured bank overdraft facilities:			
Amount used	\$ 129,149	\$ 92,012	\$ 476,968
Amount unused	<u>869,392</u>	<u>914,812</u>	<u>528,532</u>
	<u>\$ 998,541</u>	<u>\$ 1,006,824</u>	<u>\$ 1,005,500</u>
Secured bank overdraft facilities:			
Amount used	\$ 100,000	\$ -	\$ -
Amount unused	<u>300,000</u>	<u>400,000</u>	<u>400,000</u>
	<u>\$ 400,000</u>	<u>\$ 400,000</u>	<u>\$ 400,000</u>

31. TRANSACTIONS WITH RELATED PARTIES

Balances and transactions between the Company and its subsidiaries, which are related parties of the Company, have been eliminated upon consolidation and are not disclosed in this note. Besides information disclosed elsewhere in the other notes, details of transactions between the Group and other related parties are disclosed below.

Remuneration of key management personnel

	<u>For the Three Months Ended September 30</u>		<u>For the Nine Months Ended September 30</u>	
	<u>2025</u>	<u>2024</u>	<u>2025</u>	<u>2024</u>
Short-term employee benefits	\$ 5,211	\$ 4,449	\$ 30,924	\$ 27,771
Post-employment benefits	<u>89</u>	<u>84</u>	<u>267</u>	<u>252</u>
	<u>\$ 5,300</u>	<u>\$ 4,533</u>	<u>\$ 31,191</u>	<u>\$ 28,023</u>

The remuneration of directors and key executives, as determined by the remuneration committee, is based on the performance of individuals and market trends.

32. ASSETS PLEDGED AS COLLATERAL OR FOR SECURITY

The following assets were provided as collaterals for quota application and for bank borrowings or other restricted use.

	<u>September 30, 2025</u>	<u>December 31, 2024</u>	<u>September 30, 2024</u>
Property, plant and equipment	\$ 222,526	\$ 223,499	\$ 223,823
Other financial assets - non-current (presented in other non-current assets)	<u>128</u>	<u>136</u>	<u>135</u>
	<u>\$ 222,654</u>	<u>\$ 223,635</u>	<u>\$ 223,958</u>

33. SIGNIFICANT CONTINGENT LIABILITIES AND UNRECOGNIZED COMMITMENTS

In addition to those disclosed in other notes, significant commitments and contingencies of the Group were as follows:

- a. As of September 30, 2025, December 31, 2024 and September 30, 2024, the contracts signed by the Group for the purchase of equipment and application software systems were \$279,394 thousand, \$199,397 thousand and \$97,276 thousand, respectively, and the outstanding amounts were \$84,999 thousand, \$103,383 thousand and \$48,467 thousand, respectively.
- b. The Company, in response to Civil Judgment of Zhi-Zi No. 2, Year 2023 issued by the Taipei District Court, has retained legal counsel to file an appeal. On October 23, 2024, the Company received Judgment of Chongshang-Zi No. 000615, Year 2023 from the Taiwan High Court. The Company sought punitive damages of \$2,000 thousand from Li-Ju Lai due to breach of contract by opening another clinic during the contract period of Chiayi Universal Eye Center. This claim was dismissed by the Taiwan High Court. Li-Ju Lai subsequently filed a countersuit against the Company for unjust enrichment in the amount of \$21,924 thousand, which was also dismissed by the Taiwan High Court. It has been assessed that there is no material impact on the Company's finance and business. Upon receiving the court judgment, the Company has appointed legal counsel to handle the relevant legal proceedings.

34. SIGNIFICANT ASSETS AND LIABILITIES DENOMINATED IN FOREIGN CURRENCIES

The Group's significant financial assets and liabilities denominated in foreign currencies aggregated by the foreign currencies other than functional currencies of the entities in the Group and the related exchange rates between the foreign currencies and the respective functional currencies were as follows:

Currency Unit: In Thousands of New Taiwan Dollars and Foreign Currencies

September 30, 2025

	<u>Foreign Currency</u>	<u>Exchange Rate</u>	<u>Carrying Amount</u>
<u>Financial assets</u>			
Monetary items			
USD	\$ 4,112	30.4450 (USD:NTD)	\$ 125,198
USD	67	7.1055 (USD:RMB)	<u>2,055</u>
			<u>\$ 127,253</u>

December 31, 2024

	<u>Foreign Currency</u>	<u>Exchange Rate</u>	<u>Carrying Amount</u>
<u>Financial assets</u>			
Monetary items			
USD	\$ 3,961	32.7850 (USD:NTD)	\$ 129,846
USD	118	7.1884 (USD:RMB)	<u>3,853</u>
			<u>\$ 133,699</u>

September 30, 2024

	<u>Foreign Currency</u>	<u>Exchange Rate</u>	<u>Carrying Amount</u>
<u>Financial assets</u>			
Monetary items			
USD	\$ 4,195	31.6500 (USD:NTD)	\$ 132,778
USD	167	7.0074 (USD:RMB)	<u>5,301</u>
			<u>\$ 138,079</u>

The Group is mainly exposed to the USD and the RMB. The following information was aggregated by the functional currency of the Group, and the exchange rates between the functional currency and the presentation currency were disclosed. The significant realized and unrealized foreign exchange gains (losses) were as follows:

	<u>For the Three Months Ended September 30</u>			
	<u>2025</u>		<u>2024</u>	
	<u>Exchange Rate (Foreign Currency: Functional Currency)</u>	<u>Net Foreign Exchange Gains (Losses)</u>	<u>Exchange Rate (Foreign Currency: Functional Currency)</u>	<u>Net Foreign Exchange Gains (Losses)</u>
NTD	1.000 (NTD:NTD)	\$ 4,786	1.000 (NTD:NTD)	\$ (3,143)
RMB	4.271 (RMB:NTD)	<u>(15)</u>	4.523 (RMB:NTD)	<u>(90)</u>
		<u>\$ 4,771</u>		<u>\$ (3,233)</u>

	<u>For the Nine Months Ended September 30</u>			
	<u>2025</u>		<u>2024</u>	
	<u>Exchange Rate (Foreign Currency: Functional Currency)</u>	<u>Net Foreign Exchange Gains (Losses)</u>	<u>Exchange Rate (Foreign Currency: Functional Currency)</u>	<u>Net Foreign Exchange Gains (Losses)</u>
NTD	1.000 (NTD:NTD)	\$ (9,615)	1.000 (NTD:NTD)	\$ 3,241
RMB	4.271 (RMB:NTD)	<u>(31)</u>	4.523 (RMB:NTD)	<u>(57)</u>
		<u>\$ (9,646)</u>		<u>\$ 3,184</u>

35. SEPARATELY DISCLOSED ITEMS

a. Information on significant transactions:

- 1) Financing provided to others. (None)
- 2) Endorsements/guarantees provided. (Table 1)
- 3) Significant marketable securities held (excluding investment in subsidiaries, associates and joint ventures). (Table 2)
- 4) Total purchases from or sales to related parties amounting to at least NT\$100 million or 20% of the paid-in capital. (None)

- 5) Receivables from related parties amounting to at least NT\$100 million or 20% of the paid-in capital. (None)
 - 6) Intercompany relationships and significant intercompany transactions. (Table 3)
- b. Information on investees (Table 4)
- c. Information on investments in mainland China
- 1) Information on any investee company in mainland China, showing the name, principal business activities, paid-in capital, method of investment, inward and outward remittance of funds, ownership percentage, investment income or loss, carrying amount of the investment at the end of the period, repatriations of investment income, and limit on the amount of investment in the mainland China area. (Table 5)
 - 2) Any of the following significant transactions with investee companies in mainland China, either directly or indirectly through a third party, and their prices, payment terms, and unrealized gains or losses: (None)
 - a) The amount and percentage of purchases and the balance and percentage of the related payables at the end of the period.
 - b) The amount and percentage of sales and the balance and percentage of the related receivables at the end of the period.
 - c) The amount of property transactions and the amount of the resultant gains or losses.
 - d) The balance of negotiable instrument endorsements or guarantees or pledges of collateral at the end of the period and the purposes.
 - e) The highest balance, the end of period balance, the interest rate range, and total current year interest with respect to financing of funds.
 - f) Other transactions that have a material effect on the profit or loss for the year or on the financial position, such as the rendering or receipt of services.

36. SEGMENT INFORMATION

Information reported to the chief operating decision maker for the purposes of resource allocation and assessment of segment performance focuses on the types of goods or services delivered or provided. Specifically, the Group's reportable segments were as follows:

Ophthalmology Business segment - this department is responsible for providing ophthalmic clinics and hospital technical services and consultancy services and leasing services.

Optometry Business segment - this department is responsible for the sales of glasses and peripheral equipment.

Segment Revenues and Results

The following was an analysis of the Group's revenue and results from continuing operations by reportable segments:

	<u>Ophthalmology Business Division</u>	<u>Optometry Business Division</u>	<u>Reportable Segment Income</u>	<u>Adjustment and Elimination</u>	<u>Total</u>
For the nine months ended <u>September 30, 2025</u>					
Revenue					
Revenue from external customers	\$ 2,360,064	\$ 810,839	\$ 3,170,903	\$ -	\$ 3,170,903
Inter-segment revenue	<u>107,470</u>	<u>622</u>	<u>108,092</u>	<u>(108,092)</u>	<u>-</u>
Consolidated revenue	<u>\$ 2,467,534</u>	<u>\$ 811,461</u>	<u>\$ 3,278,995</u>	<u>\$ (108,092)</u>	<u>\$ 3,170,903</u>
Profit before tax (continuing operations)	<u>\$ 830,448</u>	<u>\$ 197,696</u>	<u>\$ 1,028,144</u>	<u>\$ -</u>	<u>\$ 1,028,144</u>
For the nine months ended <u>September 30, 2024</u>					
Revenue					
Revenue from external customers	\$ 2,448,998	\$ 741,189	\$ 3,190,187	\$ -	\$ 3,190,187
Inter-segment revenue	<u>169,645</u>	<u>986</u>	<u>170,631</u>	<u>(170,631)</u>	<u>-</u>
Consolidated revenue	<u>\$ 2,618,643</u>	<u>\$ 742,175</u>	<u>\$ 3,360,818</u>	<u>\$ (170,631)</u>	<u>\$ 3,190,187</u>
Profit before tax (continuing operations)	<u>\$ 841,293</u>	<u>\$ 177,874</u>	<u>\$ 1,019,167</u>	<u>\$ -</u>	<u>\$ 1,019,167</u>

Segment profit represents the profit before tax earned by each segment without interest income, other income, other gains and losses finance costs and income tax expense, however, interest income and expenses arising from IFRS 16 are related to operating activities and are therefore not excluded. This was the measure reported to the chief operating decision maker for the purpose of resource allocation and assessment of segment performance.

UNIVERSAL VISION BIOTECHNOLOGY CO., LTD. AND SUBSIDIARIES

ENDORSEMENTS/GUARANTEES PROVIDED
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2025
(In Thousands of New Taiwan Dollars, Unless Stated Otherwise)

No. (Note 1)	Endorser/Guarantor	Endorsee/Guarantee		Limits on Endorsement/ Guarantee Given on Behalf of Each Party (Note 3)	Maximum Amount Endorsed/ Guaranteed During the Period (Note 4)	Outstanding Endorsement/ Guarantee at the End of the Period (Note 5)	Actual Amount Borrowed (Note 6)	Amount Endorsed/ Guaranteed by Collaterals	Ratio of Accumulated Endorsement/ Guarantee to Net Equity in Latest Financial Statements (%)	Aggregate Endorsement/ Guarantee Limit (Note 3)	Endorsement/ Guarantee Given by Parent on Behalf of Subsidiaries (Note 7)	Endorsement/ Guarantee Given by Subsidiaries on Behalf of Parent (Note 7)	Endorsement/ Guarantee Given on Behalf of Companies in Mainland China (Note 7)	Note
		Name	Relationship (Note 2)											
0	Universal Vision Biotechnology Co., Ltd.	Kunshan Universal Trading Co., Ltd.	b.	\$ 1,114,951	\$ 99,615 US\$ 3,000,000	\$ 91,335 US\$ 3,000,000	\$ - -	\$ -	2.46	\$ 1,858,252	Y	N	Y	-
1	Kunshan Universal Trading Co., Ltd.	Hangzhou Taixue Ophthalmic Outpatient Department Ltd.	d.	126,965	46,258 RMB 10,000,000	42,847 RMB 10,000,000	10,283 RMB 2,400,000	-	1.15	126,965	N	N	Y	-

Note 1: Numbering sequence is as follows:

- The issuer is numbered 0.
- Investees are numbered sequentially starting from 1.

Note 2: The 7 types of relationships between the endorser/guarantor and endorsee/guarantees are as follows:

- Company with business transactions.
- Company where Universal Vision Biotechnology Co., Ltd. directly or indirectly holds over 50% of its voting shares.
- Company that directly or indirectly holds more 50% of the shares in Universal Vision Biotechnology Co., Ltd.
- Company where Kunshan Universal Trading Co., Ltd. directly or indirectly holds more than 90% of the voting shares.
- Companies fulfill its contractual obligations by providing mutual endorsements/guarantees for another company in the same industry or for joint builders for purposes of undertaking a construction project.
- For investment purposes, where it is necessary that all investors endorse/guarantee for the Company according to the proportion of shares held.
- Joint guarantees for performance of presale housing sales contracts conducted between industry peers in accordance with the Consumer Protection Act.

Note 3: According to Universal Vision Biotechnology Co., Ltd. Endorsement/Guarantee Provided Enforcement Rules, the amount of the guarantee provided by Universal Vision Biotechnology Co., Ltd. shall not exceed 50% of its net worth; to single associated company overseas shall not exceed 30% of its net worth. The limited amount Universal Vision Biotechnology Co., Ltd. provided to individual entity is net worth of \$3,716,503 thousand \times 30% = \$1,114,951 thousand; the total amount Universal Vision Biotechnology Co., Ltd. provided is limited to \$3,716,503 thousand \times 50% = \$1,858,252 thousand. Kunshan Universal Trading Co., Ltd. provided to individual entity is net worth of \$253,929 thousand \times 50% = \$126,965 thousand.

Note 4: The maximum balance of endorsement guarantees for others in the current period.

Note 5: Amount approved by the Company's board of directors. The Company's board follows Regulations Governing Loaning of Funds and Making of Endorsements/Guarantees by Public Companies Article 12-8 Hierarchy of decision-making authority and delegation that means the amount was decided by the chairman of the board of directors.

Note 6: Actual expenditure amount of the endorsed company within the range of the balance of the endorsement guarantee.

Note 7: "Y" must be filled in if endorsement guarantor for parent company is subsidiary company, endorsement guarantor for subsidiary company is parent company, and endorsement certificate is for mainland China company.

UNIVERSAL VISION BIOTECHNOLOGY CO., LTD. AND SUBSIDIARIES

SIGNIFICANT MARKETABLE SECURITIES HELD

SEPTEMBER 30, 2025

(In Thousands of New Taiwan Dollars, Unless Stated Otherwise)

Holding Company Name	Type and Name of Marketable Securities (Note)	Relationship with the Holding Company	Financial Statement Account	September 30, 2025				Note
				Number of Shares/Face Value	Carrying Amount	Percentage of Ownership (%)	Fair Value	
Universal Vision Biotechnology Co., Ltd.	<u>Funds and beneficiary certificates</u>							
	CTBC U.S. Treasury 20+ Year Bond ETF	None	Financial assets at fair value through profit and loss - current	5,100,000	\$ 138,108	-	\$ 138,108	
	Yuanta U.S. Treasury 20+ Year Bond ETF	None	Financial assets at fair value through profit and loss - current	5,000,000	134,350	-	134,350	
	Cathay U.S. Treasury 20+ Year Bond ETF	None	Financial assets at fair value through profit and loss - current	5,000,000	139,500	-	139,500	
	Yuanta US 20+ Year AAA-A Corporate Bond ETF	None	Financial assets at fair value through profit and loss - current	800,000	25,584	-	25,584	
	Cathay US Corporate A- and Above 10+ Years Liquid ETF	None	Financial assets at fair value through profit and loss - current	250,000	8,657	-	8,657	
	CTBC USD Corporate 10+ Year High Grade Capped Bond ETF	None	Financial assets at fair value through profit and loss - current	500,000	16,885	-	16,885	
	CTBC Banking Senior 10+ Year Bond ETF	None	Financial assets at fair value through profit and loss - current	800,000	28,640	-	28,640	
	Yuanta US 20+ Year BBB Corporate Bond ETF	None	Financial assets at fair value through profit and loss - current	750,000	25,163	-	25,163	
	CAPITAL BofA MERRILL LYNCH 10+ YEAR US BANKING INDEX EXCHANGE TRADED FUND	None	Financial assets at fair value through profit and loss - current	750,000	25,470	-	25,470	
	Cathay US Corporate 10+ Years Banking ETF	None	Financial assets at fair value through profit and loss - current	500,000	8,025	-	8,025	
	Fubon 20+ Years US Treasury Bond ETF	None	Financial assets at fair value through profit and loss - current	4,800,000	140,208	-	140,208	
	CAPITAL ICE 25+ YEAR US TREASURY EXCHANGE TRADED FUND	None	Financial assets at fair value through profit and loss - current	4,900,000	136,857	-	136,857	
	Sinopac ICE 20+ Year US Treasury ETF	None	Financial assets at fair value through profit and loss - current	6,000,000	139,200	-	139,200	
	KGI 25+ Years US Treasury Bond ETF	None	Financial assets at fair value through profit and loss - current	4,500,000	127,395	-	127,395	
	UPAMC US Treasury 20 Plus Year ETF	None	Financial assets at fair value through profit and loss - current	9,000,000	<u>122,310</u>	-	<u>122,310</u>	
						<u>\$ 1,216,352</u>		<u>\$ 1,216,352</u>
	<u>Foreign bonds</u>							
	U.S. Treasury bonds	None	Financial assets at fair value through other comprehensive income - non-current	US3,400,000	<u>\$ 104,614</u>	-	<u>\$ 104,614</u>	

Note: For information on investments in subsidiaries, affiliated companies and joint venture, refer to Tables 4 and 5.

UNIVERSAL VISION BIOTECHNOLOGY CO., LTD. AND SUBSIDIARIES

**INTERCOMPANY RELATIONSHIPS AND SIGNIFICANT INTERCOMPANY TRANSACTIONS
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2025
(In Thousands of New Taiwan Dollars, Unless Stated Otherwise)**

No. (Note 1)	Investee Company	Counterparty	Relationship (Note 2)	Transactions Details			
				Financial Statement Account	Amount	Payment Terms	% to Total Sales or Assets (Note 3)
0	Universal Vision Biotechnology Co., Ltd.	Taixue Jhongke Co., Ltd.	a	Receivables	\$ 1,016	No significant difference from general transaction	0.02
		Taixue Jhongke Co., Ltd.	a	Sales revenue	5,310	No significant difference from general transaction	0.17
		Taixue Chongde Co., Ltd.	a	Receivables	3,967	No significant difference from general transaction	0.07
		Taixue Chongde Co., Ltd.	a	Sales revenue	3,778	No significant difference from general transaction	0.12
1	Taixue Medical Investment Management (Zhejiang) Co., Ltd.	Kunshan Universal Trading Co., Ltd.	c	Sales revenue	3,330	No significant difference from general transaction	0.11
		Ningbo Haishu Taixue Ophthalmic Outpatient Department Ltd.	c	Sales revenue	21,230	No significant difference from general transaction	0.67
		Hangzhou Taixue Ophthalmic Outpatient Department Ltd.	c	Receivables	32,308	No significant difference from general transaction	0.54
		Hangzhou Taixue Ophthalmic Outpatient Department Ltd.	c	Sales revenue	32,332	No significant difference from general transaction	1.02
		Suzhou Haiweishi Ophthalmic Clinic (LP)	c	Receivables	3,328	No significant difference from general transaction	0.06
		Suzhou Haiweishi Ophthalmic Clinic (LP)	c	Sales revenue	3,603	No significant difference from general transaction	0.11
2	Kunshan Universal Trading Co., Ltd.	Taixue Medical Investment Management (Zhejiang) Co., Ltd.	c	Receivables	295	No significant difference from general transaction	-
		Taixue Medical Investment Management (Zhejiang) Co., Ltd.	c	Sales revenue	597	No significant difference from general transaction	0.02
		Ningbo Haishu Taixue Ophthalmic Outpatient Department Ltd.	c	Receivables	1,542	No significant difference from general transaction	0.03
		Ningbo Haishu Taixue Ophthalmic Outpatient Department Ltd.	c	Sales revenue	12,634	No significant difference from general transaction	0.40
		Taixue (Jiangsu) Medical Investment Management Co., Ltd.	c	Receivables	5,712	No significant difference from general transaction	0.10
		Taixue (Jiangsu) Medical Investment Management Co., Ltd.	c	Sales revenue	2,535	No significant difference from general transaction	0.08
		Hangzhou Taixue Ophthalmic Outpatient Department Ltd.	c	Receivables	43,104	No significant difference from general transaction	0.73
		Hangzhou Taixue Ophthalmic Outpatient Department Ltd.	c	Sales revenue	22,015	No significant difference from general transaction	0.69
		Suzhou Haiweishi Ophthalmic Clinic (LP)	c	Receivables	65	No significant difference from general transaction	-
		Suzhou Haiweishi Ophthalmic Clinic (LP)	c	Sales revenue	547	No significant difference from general transaction	0.02
		Taixue (Hangzhou) Glasses Co., Ltd.	c	Sales revenue	8	No significant difference from general transaction	-
		Hangzhou Taixue (II) Ophthalmic Outpatient Department Ltd.	c	Receivables	88	No significant difference from general transaction	-
		Hangzhou Taixue (II) Ophthalmic Outpatient Department Ltd.	c	Sales revenue	173	No significant difference from general transaction	0.01

Note 1: The Company and its subsidiaries are numbered as follows:

- a. The parent company is numbered 0.
- b. Subsidiaries are numbered sequentially starting from 1.

Note 2: The three types of relationships between transacting parties are as follows, the same transaction between the parent company and its subsidiary or between subsidiaries is listed only once:

- a. Represents the transactions from parent company to subsidiary.
- b. Represents the transactions from subsidiary to parent company.
- c. Represents the transactions between subsidiaries.

Note 3: The rate of the intercompany transactions to total sales or assets is calculated by the balance at the end of the period if it belongs to assets or liabilities or the accumulated amount in the interim period if it belongs to sales.

UNIVERSAL VISION BIOTECHNOLOGY CO., LTD. AND SUBSIDIARIES

INFORMATION OF INVESTEEES

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2025

(In Thousands of New Taiwan Dollars, Shares in Thousands of Shares)

Investor Company	Investee Company	Location	Main Businesses and Products	Original Investment Amount		As of September 30, 2025			Net Income (Loss) of the Investee	Share of Profit (Loss)	Note
				September 30, 2025	December 31, 2024	Number of Shares	%	Carrying Amount			
Universal Vision Biotechnology Co., Ltd.	Universal Group (BVI) Inc.	Vistra Corporate Services Centre, Wickhams Cay II, Road Town, Tortola, VG1110, British Virgin Islands	Investment	\$ 706,098	\$ 706,098	23,159	100.00	\$ 391,372	\$ (3,645)	\$ (3,645)	
	Taixue Investment Holdings Co., Ltd.	4F., No. 3-1 Yuanqu St., Nangang Dist., Taipei City 115603, Taiwan R.O.C.	Investment	150,000	150,000	15,000	100.00	106,901	(532)	(532)	
Taixue Investment Holdings Co., Ltd.	Taixue Jinghua Co., Ltd.	4F., No. 3-1 Yuanqu St., Nangang Dist., Taipei City 115603, Taiwan R.O.C.	Wholesale and retail of medical equipment, western medicine	71,000	71,000	600	100.00	9,032	(146)	(146)	
	Taixue Jhongdou Co., Ltd.	4F., No. 3-1 Yuanqu St., Nangang Dist., Taipei City 115603, Taiwan R.O.C.	Wholesale and retail of medical equipment, western medicine	65,200	65,200	6,000	100.00	11,946	67	67	
	Eyeseer Medical Inc.	4F., No. 3-1 Yuanqu St., Nangang Dist., Taipei City 115603, Taiwan R.O.C.	Wholesale and retail of medical equipment	25,000	15,000	2,500	100.00	14,019	(3,606)	(3,606)	
	Taixue Jhongke Co., Ltd.	4F., No. 3-1 Yuanqu St., Nangang Dist., Taipei City 115603, Taiwan R.O.C.	Wholesale and retail of medical equipment, western medicine	1,000	1,000	1,000	16.67	6,430	14,671	2,445	
	Taixue Chongde Co., Ltd.	4F., No. 3-1 Yuanqu St., Nangang Dist., Taipei City 115603, Taiwan R.O.C.	Wholesale and retail of medical equipment	1,000	-	1,000	16.67	1,551	3,304	551	
	Taixue Keelung Co., Ltd.	4F., No. 3-1 Yuanqu St., Nangang Dist., Taipei City 115603, Taiwan R.O.C.	Wholesale and retail of medical equipment	1,000	-	1,000	16.67	995	(33)	(5)	
	Universal Group (BVI) Inc.	Universal Group Holding Co., Ltd.	Vistra (Cayman) Limited, P.O. Box 31119 Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman KY1-1205, Cayman Islands	Investment	704,333	704,333	23,209	100.00	390,992	(3,647)	(3,647)
Universal Group Holding Co., Ltd.	Universal International (Samoa) Co., Ltd.	Vistra Corporate Services Centre, Ground Floor NPF Building, Beach Road, Apia, Samoa	Investment	697,966	697,966	23,000	100.00	390,841	(3,648)	(3,648)	

UNIVERSAL VISION BIOTECHNOLOGY CO., LTD. AND SUBSIDIARIES

INFORMATION ON INVESTMENT IN MAINLAND CHINA
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2025
(In Thousands of New Taiwan Dollars, Unless Stated Otherwise)

Investee Company	Main Businesses and Products	Paid-in Capital	Method of Investment (Note 1)	Accumulated Outward Remittance for Investment from Taiwan as of January 1, 2025	Remittance of Funds		Accumulated Outward Remittance for Investment from Taiwan as of September 30, 2025	Net Income (Loss) of the Investee	% Ownership of Direct or Indirect Investment	Investment Gain (Loss) (Note 2 b.(2))	Carrying Amount as of September 30, 2025	Accumulated Repatriation of Investment Income as of September 30, 2025
					Outward	Inward						
Universal Vision Biotechnology (Shanghai) Co., Ltd.	Purchase and sale of ophthalmic surgical instruments, medical optical instruments, etc.	US\$ 23,000,000	(b) Universal International (Samoa) Co., Ltd.	\$ 697,966	\$ -	\$ -	\$ 697,966	\$ (3,648) RMB (837,104)	100.00	\$ (3,648) RMB (837,104)	\$ 390,840 RMB 91,217,452	\$ -
Taixue (Jiangsu) Investment Co., Ltd.	Investment	RMB 143,000,000	(b) Universal Vision Biotechnology (Shanghai) Co., Ltd.	-	-	-	-	(1,303) RMB (299,117)	100.00	(1,303) RMB (299,117)	377,791 RMB 88,172,013	-
Taixue Medical Investment Management (Zhejiang) Co., Ltd.	Enterprise and medical project investment	RMB 150,000,000	(b) Taixue (Jiangsu) Investment Co., Ltd.	-	-	-	-	(2,431) RMB (557,903)	70.00	(1,702) RMB (390,532)	247,769 RMB 57,826,224	-
Kunshan Universal Trading Co., Ltd.	Import and export of medical devices and related services	RMB 59,140,000	(b) Taixue Medical Investment Management (Zhejiang) Co., Ltd.	6,367	-	-	6,367	3,423 RMB 785,490	70.00	2,402 RMB 551,188	177,714 RMB 41,476,310	-
Taixue (Jiangsu) Glasses Co., Ltd.	Wholesale and retail of glasses	RMB 9,800,000	(b) Taixue Medical Investment Management (Zhejiang) Co., Ltd.	-	-	-	-	777 RMB 178,239	70.00	544 RMB 124,767	15,057 RMB 3,514,163	-
Ningbo Haishu Taixue Ophthalmic Outpatient Department Ltd.	Ophthalmology diagnosis and eyeglasses wholesale and retail	RMB 12,000,000	(b) Taixue Medical Investment Management (Zhejiang) Co., Ltd.	-	-	-	-	(2,492) RMB (571,804)	70.00	(1,281) RMB (294,038)	33,264 RMB 7,763,427	-
Taixue (Jiangsu) Medical Investment Management Co., Ltd.	Enterprise and medical project investment, management and consulting services	RMB 29,500,000	(b) Taixue Medical Investment Management (Zhejiang) Co., Ltd.	-	-	-	-	(14,952) RMB (3,431,371)	70.00	(10,480) RMB (2,405,026)	9,847 RMB 2,298,074	-
Taixue Dixin Medical Investment Management (Hangzhou) Co., Ltd.	Healthcare investment management	RMB 22,700,000	(b) Taixue Medical Investment Management (Zhejiang) Co., Ltd.	-	-	-	-	4,354 RMB 999,263	70.00	3,615 RMB 829,565	(32,999) RMB (7,701,587)	-
Hangzhou Taixue Ophthalmic Outpatient Department Ltd.	Ophthalmology diagnosis and eyeglasses wholesale and retail	RMB 19,500,000	(b) Taixue Dixin Medical Investment Management (Hangzhou) Co., Ltd.	-	-	-	-	5,880 RMB 1,349,454	70.00	4,116 RMB 944,618	(33,901) RMB (7,912,016)	-
Suzhou Haiweishi Ophthalmic Clinic (LP)	The scope of ophthalmology and surgery is limited to outpatient surgery, and it also engages in spectacles and retail	RMB 13,300,000	(b) Taixue (Jiangsu) Medical Investment Management Co., Ltd. and Taixue Dixin Medical Investment Management (Hangzhou) Co., Ltd.	-	-	-	-	(7,406) RMB (1,699,618)	70.00	(5,184) RMB (1,189,732)	10,417 RMB 2,431,287	-
Hangzhou Lingping Taixue Ophthalmic Hospital Ltd.	Retail, medical device sales and medical services	(Note 4)	(b) Hangzhou Taixue Ophthalmic Outpatient Department Ltd.	-	-	-	-	79 RMB 18,214	70.00	56 RMB 12,750	- RMB -	-
Taixue (Hangzhou) Glasses Co., Ltd.	Wholesale and retail of glasses and sale of medical devices	RMB 4,000,000	(b) Hangzhou Taixue Ophthalmic Outpatient Department Ltd.	-	-	-	-	(2,333) RMB (535,428)	70.00	(1,633) RMB (374,800)	8,096 RMB 1,889,523	-
Hangzhou Taixue (II) Ophthalmic Outpatient Department Ltd.	Ophthalmic medical services and sale of medical devices	RMB 1,500,000	(b) Hangzhou Taixue Ophthalmic Outpatient Department Ltd.	-	-	-	-	1,148 RMB 263,498	70.00	804 RMB 184,449	2,218 RMB 517,695	-

(Continued)

Company	Accumulated Outward Remittance for Investment in Mainland China as of September 30, 2025	Investment Amounts Authorized by Investment Commission, MOEA	Upper Limit on the Amount of Investment Stipulated by the Investment Commission, MOEA
Universal Vision Biotechnology Co., Ltd.	\$ 706,098 (US\$ 23,159,000)	\$ 797,913 (US\$ 26,209,000) Exchange rate: 30.445	\$ 2,229,902

Note 1: Three methods of investment are the following:

- a. Direct investment.
- b. Reinvestment in China through a company located in a third region (specify the investment company registered in the third jurisdiction).
- c. Other methods.

Note 2: The column of investment profit and loss recognized in the current period:

- a. If it is under preparation and there is no investment profit and loss, it should be indicated.
- b. The basis for recognition of investment gains and losses is divided into the following three types, which should be indicated.
 - 1) Financial statements certified by an international accounting firm that has a cooperative relationship with an accounting firm in the ROC.
 - 2) The financial statements have been reviewed by the accountant of the parent company of Taiwan.
 - 3) Other.

Note 3: According to the "Regulations Governing the Examination of Investment of Technical Cooperation in Mainland China" updated on August 29, 2008, the upper limit of the investment amount is "60% of the net value".

Note 4: Hangzhou Lingping Taixue Ophthalmic Hospital Ltd. was approved for dissolution by the shareholders on February 14, 2025, and the deregistration was completed in August 2025.

(Concluded)